carbapenems has been researched along with imipenem, anhydrous in 532 studies
| Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (imipenem, anhydrous) | Trials (imipenem, anhydrous) | Recent Studies (post-2010) (imipenem, anhydrous) |
|---|---|---|---|---|---|
| 7,355 | 147 | 5,277 | 4,784 | 391 | 1,397 |
| Protein | Taxonomy | carbapenems (IC50) | imipenem, anhydrous (IC50) |
|---|---|---|---|
| Beta-lactamase | Pseudomonas aeruginosa | 0.15 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (3.95) | 18.7374 |
| 1990's | 94 (17.67) | 18.2507 |
| 2000's | 121 (22.74) | 29.6817 |
| 2010's | 208 (39.10) | 24.3611 |
| 2020's | 88 (16.54) | 2.80 |
| Authors | Studies |
|---|---|
| Hikida, M; Kawashima, K; Mitsuhashi, S; Yoshida, M | 1 |
| Ichihara, Y; Mikami, Y; Miyaji, M; Nishimura, C; Ohashi, S; Yazawa, K | 1 |
| Furukawa, Y; Hikida, M; Kawashima, K; Kuwao, S; Nishiki, K; Nishizawa, K; Saito, I | 1 |
| Hopkins, JA; Lami, JL; Wilson, SE | 1 |
| Bergan, T; da Fonseca, J | 1 |
| García Sánchez, JE; García-Rodriguez, JA; Sánchez de San Lorenzo, A; Trujillano, I | 1 |
| Jacobus, NV; Petersen, PJ; Testa, RT; Weiss, WJ | 1 |
| Ellis, ME; Qadri, SM; Ueno, Y | 1 |
| Gotoh, N; Nishino, T | 1 |
| Livermore, DM; Wu, PJ; Yang, YJ | 1 |
| Furukawa, Y; Hikida, M; Konno, M; Mitsuhashi, S; Nishiki, K; Tashiro, K; Ubukata, K; Yoshida, M | 1 |
| Mitsuhashi, S; Yoshida, M | 1 |
| Cullmann, W; Dick, W | 1 |
| Burman, LA; Cassinelli, G; Corigli, R; Dornbusch, K; Franceschi, G; Norrby, SR; Sassella, D | 1 |
| Nadler, HL; Pitkin, DH; Sheikh, W | 1 |
| Bauernfeind, A; Jungwirth, R; Schweighart, S | 1 |
| Livermore, DM; Yang, YJ | 1 |
| Dworkin, RJ; Kennedy, SL; Sachdeva, M; Sande, MA; Tureen, JH | 1 |
| Wiedemann, B; Zühlsdorf, M | 1 |
| Easmon, CS | 1 |
| Lahnborg, G; Nord, CE | 1 |
| Barry, AL; Jones, RN; Thornsberry, C | 1 |
| Piddock, LJ; Traynor, EA; Wise, R | 1 |
| Asad, S; Maskell, JP; Tang, T; Williams, JD | 1 |
| Dornbusch, K; Göransson, E; Kronvall, G; Mörtsell, E | 1 |
| Naden, M; Watt, B | 1 |
| Acar, JF; Gutmann, L; Kitzis, MD | 1 |
| Powell, M; Seetulsingh, P; Williams, JD | 1 |
| Giles, RE; Patel, JB | 1 |
| Chin, NX; Labthavikul, P; Neu, HC | 1 |
| Aldridge, KE; Allen, SD; Barry, AL; Fuchs, PC; Gerlach, EH; Jones, RN; Pfaller, MA | 1 |
| Bywater, MJ; Holt, HA; Reeves, DS | 1 |
| Broholm, KA; Liljedahl, AL; Norrby, SR; Schliamser, SE | 1 |
| Schliamser, SE | 1 |
| Ernst, F; Glupczynski, Y; Grenier, P; Husson, M; Klastersky, J; Van der Auwera, P | 1 |
| Iaconis, JP; Nadler, HL; Sheikh, W | 1 |
| Govan, JR; Hunter, R; Simpson, IN | 1 |
| Fanta, J; Felbr, O; Lochmann, O; Pelák, Z; Vyhnánek, F | 1 |
| Bonner, DP; Fung-Tomc, J; Gradelski, E; Huczko, E; Kessler, RE; Kolek, B; Minassian, B | 1 |
| Dib, C; Jarlier, V; Trias, J | 2 |
| Andrews, JM; Boswell, FJ; Gill, MJ; Wise, R | 1 |
| Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P | 2 |
| Hirouchi, Y; Hori, R; Inui, K; Kamiya, A; Kawahara, Y; Naganuma, H; Okada, R | 1 |
| Brismar, B; Eklund, AE; Nord, CE | 1 |
| Fukatsu, H; Hashizume, T; Matsuda, K; Nakagawa, S; Okamoto, O; Sanada, M; Tanaka, N | 1 |
| Higashi, K; Nishi, T; Sato, M; Takemura, M | 1 |
| Gutmann, L; Kitzis, MD; Zhou, XY | 1 |
| Barry, AL; Fuchs, PC | 1 |
| Cipriani, P; Filadoro, F; Giordano, A; Magni, A; Papa, F | 1 |
| Cravarezza, P; Romanelli, G | 1 |
| Diwok, K; Hamacher, J; Kohl, FV; Lichey, J; Lode, H; Vogel, F; Wendel, H | 1 |
| Geroulanos, SJ | 1 |
| Hashizume, T; Hazumi, N; Kato, Y; Matsuda, K | 1 |
| Barry, AL; Brown, SD; Fuchs, PC | 3 |
| Aujard, Y | 1 |
| Baldassarre, R; Comunale, L; Poletti, G; Tallarigo, C | 1 |
| Cama, L; Kropp, H; Sasor, MW; Sundelof, JG; Thompson, R; White, KM | 1 |
| Ballestero, S; Baquero, F; Escobar, H; Fernández-Rodríguez, A; Pérez-Díaz, JC; Villaverde, R | 1 |
| Marumo, K; Nagaki, T; Nakamura, Y | 1 |
| Blumer, JL | 1 |
| Kumazawa, J; Matsumoto, T; Nagayama, A | 1 |
| Norrby, SR | 1 |
| Jiang, GZ; Kato, Y; Kido, N; Koide, N; Kusumi, A; Narita, K; Sugiyama, T; Takahashi, K; Yokochi, T | 1 |
| Matsumura, N; Minami, S; Mitsuhashi, S | 1 |
| Bradford, PA; Bush, K; Mariano, N; Projan, SJ; Rahal, JJ; Urban, C | 1 |
| Grausova, S; Koren, P; Krcmery, V; Krupova, I; Kukuckova, E; Kunova, A; Lacka, J; Spanik, S; Trupl, J | 1 |
| Adachi, Y; Fuse, A; Hashizume, T; Kato, E; Nagano, R; Nakagawa, S; Ohtake, N; Okamoto, O; Shibata, K | 1 |
| Kanazawa, K; Nouda, H; Sunagawa, M | 1 |
| Cornaglia, G; Fontana, R; Mazzariol, A; Satta, G | 1 |
| Keil, S; Wiedemann, B | 1 |
| Akama, M; Araki, H; Iyobe, S; Minami, S; Mitsuhashi, S; Narita, H; Watanabe, Y | 1 |
| Livermore, DM | 1 |
| Howe, RA; Millar, MR; Walsh, TR; Wilson, MP | 1 |
| Hostacká, A | 2 |
| Chang, DC; Wilson, SE | 1 |
| Asano, K; Fuse, A; Hashizume, T; Nagano, R; Naito, T; Nakagawa, S; Shibata, K | 1 |
| Adachi, Y; Hashizume, T; Hazumi, N; Kato, Y; Nakagawa, S; Nakamura, K | 1 |
| Kato, Y; Koide, N; Narita, K; Sugiyama, T; Takahashi, K; Yokochi, T; Yoshida, T | 1 |
| Danel, F; Livermore, DM; Villar, HE | 1 |
| Hirata, Y; Igari, J; Imafuku, Y; Inoue, M; Ishigo, S; Kawaguchi, R; Kobayashi, I; Kumasaka, K; Matsuoka, K; Murakami, E; Nishino, T; Oguri, T; Ohtaki, Y; Okada, J; Okamoto, E; Saeki, H; Satou, S; Shibano, T; Takahashi, A; Tokuda, K; Uchida, K; Uehara, N; Watanabe, N; Yomoda, S; Yoshida, H | 1 |
| Kimpara, I; Kudo, E; Kudo, H; Kudo, Y; Miura, T; Saitoh, Y; Sato, S; Tsujino, M | 1 |
| Garau, J; Martínez Lacasa, J | 1 |
| Abe, T; Domon, H; Fukuoka, T; Harasaki, T; Hirasawa, A; Ishii, C; Iwata, M; Kakuta, M; Kawada, H; Koga, T; Kubota, M; Kuwahara, S; Masuda, N; Ohya, S; Sakagawa, E; Takenouchi, T; Utsui, Y; Yasuda, H | 1 |
| Blanquer, J; Cobo, L; Corcia, S; Daguerre, M; de Latorre, FJ; Del Nogal, F; Garau, J; León, C; Net, A; Rello, J | 1 |
| Cuca, GC; Hammond, GG; Leiting, B; Pompliano, DL; Pryor, KD; Toney, JH; Wu, JK | 1 |
| Eltahawy, AT | 1 |
| Awaya, Y; Fujiue, Y; Kodomari, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y | 1 |
| Groeneveld, PH; Kwappenberg, KM; Mattie, H; van Dissel, JT; van Langevelde, P | 1 |
| Benali, K; Bingen, E; Bonacorsi, S; Doit, C; Fitoussi, F; Geslin, P | 1 |
| Ambrose, PG; Nightingale, CH; Quintiliani, R; Richerson, MA | 1 |
| Babini, GS; Livermore, DM; Yuan, M | 1 |
| Nakae, T; Ono, T; Yoneyama, H; Yoshihara, E | 1 |
| Alarcón, T; López-Brea, M; López-Hernández, S | 1 |
| Babini, GS; Bates, J; Livermore, DM; Palepou, MF; Woodford, N | 1 |
| Imamura, H; Jona, H; Kiyonaga, H; Moriya, M; Nakagawa, S; Nakano, M; Ohtake, N; Sato, H; Shimizu, A; Ushijima, R | 1 |
| Cars, O; Löwdin, E; Odenholt, I | 1 |
| Kinoshita, S; Kumagai, S | 1 |
| Bitha, P; Jacobus, NV; Lin, YI; Petersen, PJ; Testa, RT; Weiss, WJ | 1 |
| Amyes, AK; Amyes, SG; Payne, DJ; Stunt, RA; Thomson, CJ | 1 |
| Horii, T; Ichiyama, S; Kobayashi, M; Ohta, M | 1 |
| Afzal-Shah, M; Livermore, DM; Villar, HE | 1 |
| Hirata, Y; Hongo, T; Igari, J; Imafuku, Y; Inoue, M; Kawaguchi, R; Kobayashi, I; Kobayasi, Y; Kumasaka, K; Matsumoto, N; Nakasaki, N; Nishino, T; Oguri, T; Ohtaki, Y; Okada, J; Saeki, H; Sasaki, T; Satou, S; Shibano, T; Takahashi, A; Tokuda, K; Uehara, N; Watanabe, N; Yomoda, S; Yoshida, H | 1 |
| Hikida, M; Igarashi, A; Itahashi, K; Kitamura, M; Shiba, T | 1 |
| Collatz, E; Jarlier, V; Naas, T; Nordmann, P; Sougakoff, W | 1 |
| Cardoso, O; Leitão, R; Peixe, L; Sousa, JC | 1 |
| Allerberger, F; Feierl, G; Hirschl, A; Krause, R; Mittermayer, H; Reisinger, EC; Wendelin, I | 1 |
| Arita, K; Daido, K; Kohara, T; Nakamura, K; Ohashi, N; Takeshima, Y | 1 |
| Cho, JH; Jin, C; Jung, I; Kim, DH; Kim, M; Ku, HJ; Oh, CH; Yook, J | 1 |
| Adachi, Y; Hashizume, T; Imamura, H; Morishima, H; Nagano, R; Shibata, K | 1 |
| Fujimura, S; Gomi, K; Honda, Y; Kikuchi, T; Kobayashi, T; Nukiwa, T; Shoji, S; Takahashi, H; Tokue, Y; Watanabe, A; Yasui, S | 1 |
| Deguchi, K; Endo, H; Ishihara, R; Matsumoto, Y; Nishinari, C; Suzuki, Y | 1 |
| Adachi, Y; Hashizume, T; Morishima, H; Nagano, R | 1 |
| Jacolot, A; Leotard, S; Louchahi, K; Mimoz, O; Nordmann, P; Padoin, C; Petitjean, O | 1 |
| Aoki, N; Hashimoto, T; Hirata, Y; Hongo, T; Igari, J; Imafuku, Y; Inoue, M; Ishigo, S; Kajimura, K; Kawaguchi, R; Kobayashi, I; Kobayashi, Y; Kumasaka, K; Matsumoto, N; Matsuoka, K; Murakami, E; Nakasaki, N; Nishino, T; Oguri, T; Ohba, Y; Ohtaki, Y; Okada, J; Okamoto, E; Ono, J; Saeki, H; Sasaki, T; Satou, S; Shibano, T; Takahashi, A; Takata, T; Tokuda, K; Uehara, N; Watanabe, N; Yomoda, S; Yoshida, H | 1 |
| Christenson, JC; Daly, JA; Korgenski, EK | 1 |
| Bou, G; Cerveró, G; Domínguez, MA; Martínez-Beltrán, J; Quereda, C | 1 |
| Cassetta, MI; Conti, S; Fallani, S; Mazzei, T; Novelli, A | 1 |
| Alberti, S; Anderson, GJ; Biddle, JW; Bush, K; Domenech-Sanchez, A; Queenan, AM; Steward, CD; Tenover, FC; Yigit, H | 1 |
| Breuil, J; Collatz, E; Monsempes, C; Podglajen, I; Rohaut, A | 1 |
| Dascal, A; Miller, MA; Zaharatos, GJ | 1 |
| Endo, H; Jinbo, K; Nishinari, C; Suzuki, Y; Tamura, C | 1 |
| Anthony, L; Appelbaum, PC; Credito, K; Ednie, LM; Hoellman, DB; Jacobs, MR; Kelly, LM | 1 |
| Choi, SH; Kim, GW; Park, HS; Park, SW; We, JS | 1 |
| Hikida, M; Inoue, M; Okamoato, R; Sato, Y; Terashima, S | 1 |
| Majtán, V; Majtánová, L | 1 |
| Nagayama, A; Nomura, S | 1 |
| Chinzei, T; Ishida, A; Tasaka, K | 1 |
| Abe, T; Fukuoka, T; Inoue, M; Ishii, C; Kakuta, M | 1 |
| Bachinskaia, EN; Beloborodova, NV | 1 |
| Pietroski, N; Schlossberg, D | 1 |
| Giller, RH; Nelson, WK; Quinones, R; Rayback, PA | 1 |
| Ho, SE; Navaratnam, P; Palasubramaniam, S; Subramaniam, G | 1 |
| Cravarezza, P; Donati, P; Franchino, L; Grassi, V; Pozzi, A; Prometti, P; Ravizzola, G; Romanelli, G; Zulli, R | 1 |
| Mikamo, H; Ninomiya, M; Tamaya, T | 1 |
| Araake, M; Hara, T; Watabe, H | 1 |
| Hashimoto, H; Horii, T; Kanno, T; Maekawa, M; Morita, M; Muramatsu, H | 1 |
| Ergen, K; Karadenizli, A; Kolayli, F; Leblebicioglu, H; Okay, E; Oz, S; Savli, H; Vahaboglu, H | 1 |
| Hashimoto, K; Ito, K; Ogata, H | 1 |
| Alberti, S; Biddle, JW; Bush, K; Domenech-Sanchez, A; Queenan, AM; Rasheed, JK; Tenover, FC; Yigit, H | 1 |
| Orlov, VA; Shenderovich, VA; Smirnova, LB; Sokolova, VI | 1 |
| Inoue, M; Kaku, M; Nasu, M; Sagawa, K; Yokoyama, T | 1 |
| Kong, HS; Xu, GY; Xu, XW; Yang, Q; Yu, YS; Zhong, BY | 1 |
| Calvo, F; Canduela, MJ; Gallego, L; Martín, G; Pujana, I; Sevillano, E; Umaran, A | 1 |
| Bernabeu-Wittel, M; García-Curiel, A; Jiménez-Mejías, ME; Pachón, J; Pachón-Ibáñez, ME; Pichardo, C | 1 |
| Axtell, SS; Callahan, J; Shekar, R; Sodhi, M | 1 |
| Brink, AJ; Feldman, C; Grolman, DC; Muckart, D; Pretorius, J; Richards, GA; Senekal, M; Sieling, W | 1 |
| Dubouix, A; Héritier, C; Marty, N; Nordmann, P; Poirel, L | 1 |
| Castanheira, M; Jones, RN; Mendes, RE; Sader, HS; Toleman, M; Walsh, TR | 1 |
| Burgess, DS; Frei, CR; Moczygemba, LR | 1 |
| Amyes, SG; Brown, S; Young, HK | 1 |
| Bernabéu-Wittel, M; de Cueto, M; del Carmen Conejo, M; García, I; Jiménez-Mejías, ME; Martínez-Martínez, L; Pachón, J; Pachón-Ibáñez, ME; Pascual, A; Pichardo, C | 1 |
| Gales, AC; Reis, AO; Sader, HS; Silbert, S | 1 |
| El Amin, N; Giske, CG; Jalal, S; Keijser, B; Kronvall, G; Wretlind, B | 1 |
| Fretland, AA | 1 |
| Beceiro, A; Bou, G; Canle, D; Cartelle, M; Cisneros, JM; del Mar Tomas, M; Llinares, P; Molina, F; Pertega, S; Villanueva, R | 1 |
| Kiribayashi, Y; Maeda, Y; Murakami, T; Nagai, J; Omoda, K; Takano, M; Yumoto, R | 1 |
| Chae, HS; Chang, E; Cho, SG; Kang, CS; Kim, JY; Lee, HK; Park, YJ | 1 |
| Majiduddin, FK; Palzkill, T | 1 |
| Hemalatha, V; Kamat, V; Sekar, U | 1 |
| Engel, AE; Glass, D; Li, C; Wexler, HM | 1 |
| Bratu, S; Landman, D; Quale, J; Salvani, JK | 1 |
| Akan, OA; Uysal, S | 1 |
| Bertini, A; Carattoli, A; Giordano, A; Mancini, C; Varesi, P; Villa, L | 1 |
| Jacoby, GA; Walker, VJ; Walsh, KE | 1 |
| Katsifa, H; Kontodimou, A; Polemis, M; Tsorlini, H; Tzouvelekis, LS; Vatopoulos, AC; Vourli, S | 1 |
| Cheng, KC; Chuang, YC; Huang, GC; Wu, LT; Yu, WL | 1 |
| Doi, M; Fujiue, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y; Yano, S | 1 |
| Fujimoto, S; Ike, Y; Sakyo, S; Tanimoto, K; Tomita, H | 1 |
| Ariza, J; Domínguez, MA; Gudiol, F; Montero, A; Peña, C; Pujol, M; Saballs, M; Tubau, F | 1 |
| Carmeli, Y; Chmelnitsky, I; Leavitt, A; Navon-Venezia, S; Schwaber, MJ; Schwartz, D | 1 |
| Biddle, JW; Carey, RB; Hanna, B; Kalsi, RK; Lonsway, D; McGowan, JE; Rasheed, JK; Stocker, S; Tenover, FC; Williams, PP | 1 |
| Ikonomidis, A; Markogiannakis, A; Pournaras, S; Spanakis, N; Tsakris, A | 1 |
| Bush, K; Lolans, K; Queenan, AM; Quinn, J; Schreckenberger, P; Shang, W | 1 |
| Hernández, JR; Martínez-Martínez, L; Pascual, A; Romero, L; Velasco, C | 1 |
| Bernander, S; Ericson, E; Fraenkel, CJ; Larsson, P; Melhus, A; Rydberg, J; Törnqvist, E; Ullberg, M | 1 |
| Donskey, CJ; Pultz, NJ; Stiefel, U | 1 |
| Edwards, R; Fang, H; Hedberg, M; Nagy, E; Nord, CE; Sóki, J | 1 |
| Archontoulis, N; Giamarellos-Bourboulis, EJ; Giamarellou, H; Mega, A; Pavleas, I; Rigas, K; Thomopoulos, G; Vernikos, P | 1 |
| Alp, E; Aygen, B; Metan, G; Sumerkan, B | 1 |
| Ikonomidis, A; Maniatis, AN; Markogiannakis, A; Pournaras, S; Spanakis, N; Tsakris, A | 1 |
| Cho, DT; Choi, CH; Kang, HY; Kim, J; Kim, KW; Lee, JC; Lee, JH; Lee, JY; Lee, YC; Seol, SY; Song, DY | 1 |
| Gfröer, S; Knabbe, C; Rahmig, H; Schroeppel, K; Susa, M; Weile, J | 1 |
| Andrade, SS; Campana, EH; Gales, AC; Nicoletti, AG; Picão, RC; Pignatari, AC | 1 |
| Ariza, J; Dominguez, MA; Gudiol, F; Guzmán, A; Peña, C; Pujol, M; Suarez, C; Tubau, F | 1 |
| Barauskas, G; Dambrauskas, Z; Gulbinas, A; Pundzius, J | 1 |
| Dilay, L; Hoban, DJ; Karlowsky, JA; Noreddin, AM; Rubinstein, E; Thomson, K; Wiebe, R; Zhanel, GG | 1 |
| Fujimura, S; Nakano, Y; Sato, T; Shirahata, K; Watanabe, A | 1 |
| Evans, JC; Segal, H | 1 |
| Katsube, T; Yamano, Y; Yano, Y | 1 |
| Chen, M; Guo, P; Sun, H; Wang, H; Xu, Y; Yang, Q; Zhu, Y | 1 |
| Durante-Mangoni, E; Fortunato, R; Tripodi, MF; Utili, R; Zarrilli, R | 1 |
| Amyes, SG; Walsh, F | 1 |
| Lister, PD | 1 |
| Amyes, S; Bracher, S; Turner, P; Walsh, F | 1 |
| Limansky, AS; Mussi, MA; Relling, VM; Viale, AM | 1 |
| Nicolau, DP | 1 |
| Deptuła, A; Gierlotka, K; Gospodarek, E; Michalska, A | 1 |
| Levi, K; Towner, KJ; Vlassiadi, M | 1 |
| Joo, JY; Kim, JH; Kwon, OH; Lee, SG | 1 |
| Shah, PM | 1 |
| Malczynski, M; Parker, M; Qi, C; Scheetz, MH | 1 |
| Gianneli, D; Loli, A; Miriagou, V; Tzelepi, E; Tzouvelekis, LS | 1 |
| Cai, JC; Chen, GX; Yang, L; Zhang, R; Zhou, HW | 1 |
| Hori, S; Kizu, J; Kurihara, Y | 1 |
| Fukumoto, A; Hanaki, H; Kim, YP; Omura, S; Shiomi, K; Tomoda, H | 1 |
| Joseph, J; Rodvold, KA | 1 |
| Ivanov, DV | 1 |
| Berkani, A; Eb, F; Mammeri, H; Nordmann, P | 1 |
| Chastre, J; Friedland, I; Kaniga, K; Lee, M; Prokocimer, P; Wunderink, R | 1 |
| Gilbert, D | 1 |
| Friedland, I; Gast, C; Ingham, M; Ketter, N; Lee, M; Merchant, S; Nathwani, D; Quintana, A | 1 |
| Alba, V; Blasco, MD; Espinal, P; Fernández-Cuenca, F; Marti, S; Pascual, A; Ruiz, M; Sánchez-Céspedes, J; Vila, J | 1 |
| Fukuoka, T; Kakuta, M; Koga, T; Masuda, N; Namba, E; Sugihara, C | 1 |
| Appelbaum, PC; Glupczynski, Y; Lemaire, S; Olivier, A; Tulkens, PM; Van Bambeke, F | 1 |
| Chen, YG; Li, LJ; Qu, TT; Shen, P; Wei, ZQ; Yu, YS; Zhang, Y | 1 |
| Bogaerts, P; Cuzon, G; Glupczynski, Y; Huang, TD; Naas, T; Nordmann, P | 1 |
| Cheong, HJ; Kim, WJ; Lee, J; Song, JY; Sung, AK | 1 |
| Blanchet, B; Chhun, S; Jullien, V; Lanternier, F; Legrand, T; Pons, G; Rey, E; Zahar, JR | 1 |
| Carey, PR; Kalp, M | 1 |
| Alba, V; Marti, S; Sánchez-Céspedes, J; Vila, J | 1 |
| Porath, AD | 1 |
| Ha, JR; Kim, BO; Kim, HG; Kim, JG; Kim, JM; Lee, DG; Lee, JM; Lee, SH; Oh, SW | 1 |
| Balogh, B; Füzi, M; Lepsanovic, Z; Libisch, B; Nonkovici, Z; Tomanovic, B | 1 |
| Cleveland, KO; Gelfand, MS; Mazumder, SA | 1 |
| Cho, JH; Kim, SJ; Oh, CH | 1 |
| Restrepo, MI | 1 |
| Amin, A | 1 |
| Higgins, PG; Lehmann, M; Nordmann, P; Poirel, L; Seifert, H | 1 |
| Bahram, F; Emaneini, M; Fatolahzadeh, B; Feizabadi, MM; Mehdi, FM; Mohammad, E; Morovat, T; Setareh, S; Soroush, S; Taherikalani, M | 1 |
| Kurata, Y; Kurosawa, T; Nawa, T; Shibasaki, S; Suzuki, H; Yagi, Y | 1 |
| Bush, K; Flamm, R; Queenan, AM; Shang, W | 1 |
| Aggoune-Khinache, N; Bonnet, R; Delmas, J; Naim, M; Robin, F | 1 |
| Blizzard, TA; Chen, H; Felcetto, T; Fitzgerald, P; Ha, S; Hairston, N; Hammond, ML; Hermes, J; Hickey, E; Kim, S; Lee, SH; Lu, J; Misura, A; Ogawa, A; Painter, RE; Park, YW; Raghoobar, S; Sharma, N; Wu, J; Young, K | 1 |
| Akhras, K; DeLong, K; Ingham, M; McGarry, LJ; Merchant, S; Nathwani, D; Pawar, V; Thompson, D; Weinstein, MC | 1 |
| Amornnopparattanakul, S; Dhiraputra, C; Fungwithaya, S; Leelarasamee, A; Nannha, P; Panapakdee, S; Pongpech, P | 1 |
| Bied, A; Brown, D; Bush, K; Drusano, GL; Fregeau, C; Kahn, JB; Khashab, M; Kulawy, R; Liu, W; Louie, A; Morrow, B; Nicholson, S; Queenan, AM; Van Scoy, B | 1 |
| Appelbaum, PC; Credito, K; Kosowska-Shick, K | 1 |
| Esterly, JS; Malczynski, M; Qi, C; Scheetz, MH | 1 |
| Chiang, PC; Chiu, CH; Huang, CT; Huang, PY; Leu, HS; Shie, SS; Su, LH; Ye, JJ | 1 |
| Gast, C; Ketter, N; Kollef, MH; Merchant, S; Nathwani, D; Quintana, A | 1 |
| Dubreuil, L; Jean-Pierre, H; Mahieux, S; Marchandin, H; Miara, A; Muller-Serieys, C; Neut, C; Soussy, CJ | 1 |
| dos Santos, RP; Goldani, LZ; Jacoby, T | 1 |
| Naenna, P; Noisumdaeng, P; Pongpech, P; Tribuddharat, C | 1 |
| Barajas, JM; Carrillo-Quiroz, B; Garza-Ramos, JU; Rojas-Moreno, T; Sanchez-Martinez, G; Sanchez-Perez, A; Silva-Sanchez, J; Suarez, S | 1 |
| Anderson, KF; Bonomo, RA; Endimiani, A; Hujer, AM; Kitchel, B; Patel, JB; Rasheed, JK | 1 |
| Chen, J; Mody, SH; Shorr, AF; Zilberberg, MD | 1 |
| Crandon, JL; Keel, RA; Nicolau, DP; Sutherland, CA | 1 |
| Eb, F; Guillon, H; Mammeri, H; Nordmann, P | 1 |
| Cantón, R; García, A; Gimeno, C; Gobernado, M | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Guitton, C; Jacqueline, C; Le Mabecque, V; Miégeville, AF; Potel, G; Villers, D | 1 |
| Cassettari, M; Chongthaleong, A; Christiansen, KJ; Cooper, D; Flamm, R; Garcia, J; Hsu, L; Ip, M; Ker, HB; Kiratisin, P; Mendoza, M; Morrissey, I; Okolo, P; Quintana, A; Redjeki, IS | 1 |
| Ko, KS; Lee, H; Peck, KR; Song, JH | 1 |
| Adams-Haduch, JM; Bogdanovich, T; Doi, Y; Pasculle, AW; Quinn, JP; Tian, GB; Wang, HN | 1 |
| Abbanat, D; Barron, A; Bunting, RA; Fernandez, J; Flamm, RK; Hall, L; Hilliard, JJ; Lynch, AS; Melton, JL; Ward, CK | 1 |
| Du, X; Jiang, X; Li, G; Wang, Y; Wei, Q; Zhao, Y | 1 |
| Gomersall, C; Kuti, JL; Kwa, A; Montakantikul, P; Nicolau, DP; Roberts, JA | 1 |
| Cai, J; Liu, J; Wu, D | 1 |
| Abbasi, L; Farajnia, S; Hasani, A; Mirsalehian, A; Nahaei, MR; Peymani, A; Sohrabi, N | 1 |
| Appelbaum, PC; Armstrong, ES; Kosowska-Shick, K; Kubo, A; Lin, G; Pankuch, GA | 1 |
| Chiang, T; Colon-Urban, R; Eng, RH; Gomez, E; Huang, DB; Mariano, N; Urban, C | 1 |
| Ersoy, Y; Görgeç, S; Kuzucu, C; Yetkin, F | 1 |
| Cabot, G; Macia, MD; Martínez-Martínez, L; Moya, B; Ocampo-Sosa, AA; Oliver, A; Peña, C; Rodríguez, C; Suárez, C; Tubau, F; Zamorano, L | 1 |
| Flamm, RK; Korten, V; Laeuffer, JM; Morrissey, I; Mutters, R; Nordmann, P; Picazo, JJ; Quintana, A; Seak, JC | 1 |
| Hsueh, PR; Huang, WH; Ko, WC; Lee, NY; Tsui, KC | 1 |
| Apisarnthanarak, A; Apisarnthanarak, P; Kiratisin, P; Mundy, LM | 1 |
| Goessens, WH; Mol, M; Pitout, JD; van der Bij, AK; van Westreenen, M | 1 |
| Hong, KW; Jeong, H; Kang, MW; Kim, SI; Kim, YJ; Kim, YR; Park, YJ; Wie, SH | 1 |
| Fukuchi, K; Gomi, K; Takahashi, N; Wakuta, R; Yamaguchi, F | 1 |
| Akalın, H; Akova, M; Arman, D; Aygen, B; Başaran, S; Bayramoğlu, G; Dizbay, M; Dokuzoğuz, B; Eraksoy, H; Esener, H; Hasçelik, G; Köksal, I; Korten, V; Oğünç, D; Sınırtaş, M; Söyletir, G; Sümerkan, B; Tünger, A; Ulusoy, S; Yalçın, AN | 1 |
| Cabot, G; Cantón, R; del Campo, R; García-Castillo, M; Juan, C; Mulet, X; Oliver, A; Riera, E | 1 |
| Carmeli, Y; Lidji, SK; Navon-Venezia, S; Schwaber, MJ; Shabtai, E | 1 |
| Bogaerts, P; Cuzon, G; Glupczynski, Y; Huang, TD; Kostyanev, T; Naas, T; Nordmann, P; Ozsu, S | 1 |
| Catel-Ferreira, M; Coadou, G; Dé, E; Jouenne, T; Molle, V; Mugnier, P; Nordmann, P; Siroy, A | 1 |
| Kim, J; Kim, S; Kim, SM; Lee, HW; Seol, SY | 1 |
| Amsler, K; Davies, TA; Flamm, RK; He, W; Lynch, AS; Marie Queenan, A; Morrow, BJ; Pillar, C; Shang, W | 1 |
| Akers, KS; Beckius, ML; Calvano, T; Hospenthal, DR; Markelz, AE; Mende, K; Murray, CK; Yu, X; Zera, WC | 1 |
| Choi, JY; Jung, SI; Kim, DH; Kim, SH; Ko, KS; Park, KH; Park, YK | 1 |
| Baek, JY; Kang, CI; Ko, KS; Peck, KR; Song, JH | 1 |
| Bonomo, RA; Endimiani, A; Papp-Wallace, KM; Taracila, MA | 1 |
| Ben, RJ; Chien, ST; Hsueh, JC; Shiang, JC; Yang, MC | 1 |
| Bustamante, Z; Fernández, E; Gallego, L; Rosales, I; Sevillano, E; Umaran, A; Zabalaga, S | 1 |
| Balkan, N; Ilki, A; Ozel, N; Söyletir, G; Toprak Ülger, N | 1 |
| Jung, SI; Kim, SH; Ko, KS; Park, KH; Park, YK | 1 |
| Chang, KC; Kuo, HY; Kuo, JW; Liou, ML; Yueh, HW | 1 |
| Chang, SC; Chen, WC; Chen, YC; Hu, FC; Wang, JL; Wu, UI; Yang, CS | 1 |
| Chen, CC; Chen, CH; Chiang, SR; Chuang, YC; Ko, WC; Lee, NY; Shieh, JM; Tang, HJ | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Desessard, C; Guitton, C; Jacqueline, C; Le Mabecque, V; Miégeville, AF; Potel, G; Villers, D | 1 |
| Firsov, AA; Gilbert, D; Greer, K; Portnoy, YA; Zinner, SH | 1 |
| Hagihara, M; Kuti, JL; Nicolau, DP | 1 |
| Chau, F; Fantin, B; Le, P; Lefort, A; Lepeule, R; Massias, L; Nucci, A; Ruppé, E | 1 |
| Badal, RE; Boffard, KD; Botha, RF; Brink, AJ; Feldman, C; Grolman, DC; Joubert, I; Poswa, X; Pretorius, J; Richards, GA; Senekal, M; Veller, M | 1 |
| Decker-Burgard, S; Laeuffer, J; Morrissey, I; Mutters, R; Seifert, H; Valenza, G | 1 |
| Chayakul, P; Garey, KW; Pattharachayakul, S; Santimaleeworagun, W; Tansakul, P; Wongpoowarak, P | 1 |
| Almuzara, M; Docquier, JD; Gutkind, G; Pollini, S; Radice, M; Rossolini, GM; Santella, G | 1 |
| Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V | 1 |
| Chen, CC; Cheng, KC; Chiang, SR; Chiu, YH; Chuang, YC; Ko, WC; Ku, YH; Tang, HJ; Zhang, CC | 1 |
| Farajnia, S; Higgins, PG; Nahaei, MR; Peymani, A; Seifert, H | 1 |
| Chang, KT; Hirsch, EB; Ledesma, KR; Motyl, MR; Schwartz, MS; Tam, VH | 1 |
| Aleo, A; Bonura, C; Brunelli, T; Degl'Innocenti, R; Fasciana, T; Mammina, C; Nastasi, A; Pesavento, G | 1 |
| Han, L; He, X; Huang, L; Li, X; Liu, D; Liu, F; Liu, W; Shao, C; Wang, J; Wang, S; Wang, X; Wang, Y; Wei, X; Yang, Z; Yin, Z; Yuan, J; Zhu, L; Zou, D | 1 |
| Alberti, S; Beceiro, A; Cabot, G; Juan, C; Moyá, B; Oliver, A; Zamorano, L | 1 |
| Bou, G; Fernández-Cuenca, F; Gómez-Sánchez, M; Martínez-Martínez, L; Pascual, A; Rodríguez-Baño, J; Vila, J | 1 |
| Dundar, D; Kasap, M; Kolayli, F; Torol, S; Vahaboglu, H | 1 |
| Aiello, E; D'Ancona, F; Dematte, L; Goglio, A; Meledandri, M; Pantosti, A; Raglio, A; Rossolini, GM; Serra, R; Sisto, A | 1 |
| Dowzicky, MJ; Fernández-Canigia, L | 1 |
| Chang, SC; Dong, SX; Wang, JT | 1 |
| Keel, RA; Kiratisin, P; Nicolau, DP | 1 |
| Chastre, J; Cirillo, I; Clavel, M; Kaniga, K; Kimko, H; Kollef, MH; Michiels, B; Redman, R; Restrepo, MI | 1 |
| Colakoğlu, S; Durmaz, S; Ekincioğlu, P; Perçin, D | 1 |
| Adamski, P; Bulanda, M; Drzewiecki, A; Sodo, A; Talaga, K | 1 |
| Martin-Loeches, I; Torres, A | 1 |
| Dantier, C; Desarbre, E; Gebhardt, K; Hofer, B; Page, MG; Schmitt-Hoffmann, A | 1 |
| Kaniga, K; Lee, M; Redman, R; Rice, DA | 1 |
| Álvarez-Buylla, A; Culebras, E; Picazo, JJ | 1 |
| Citron, DM; Goldstein, EJ; Merriam, CV; Tyrrell, KL | 1 |
| Goff, DA; Nicolau, DP | 1 |
| Guzek, A; Korzeniewski, K; Nitsch-Osuch, A; Prokop, E; Rybicki, Z | 1 |
| Kirikae, T; Miyoshi-Akiyama, T; Shimada, K; Shimojima, M; Tada, T | 1 |
| Bao, Y; Cai, Y; Chai, T; Gao, J; Li, X; Ma, R; Zhao, X; Zhou, Y | 1 |
| Lü, XJ; Wang, XH; Zong, ZY | 1 |
| Kurtinecz, M; Li, G; Mitrani-Gold, FS; Mundy, LM; Singh, KP; Tomayko, JF; Wetherington, J | 1 |
| Bozkurt, F; Dal, T; Dayan, S; Deveci, Ö; Tekin, A; Tekin, R | 1 |
| Arthur, M; Cordillot, M; Dubée, V; Dubost, L; Hugonnet, JE; Mainardi, JL; Marie, A; Triboulet, S | 1 |
| Diza, E; Exindari, M; Haitoglou, C; Meletis, G; Pournaras, S; Protonotariou, E; Sianou, E; Sofianou, D; Vavatsi, N | 1 |
| Feng, JA; Hsieh, WS; Wang, NY; Weng, LC; Wu, HH | 1 |
| Chlebicki, MP; Kwa, AL; Lee, AL; Lee, W; Liew, LT; Lim, CL; Nah, SC; Wan, CN | 1 |
| Chen, Z; Kang, M; Li, D; Tao, C; Wang, T; Xie, Y | 1 |
| Aubry, A; Bréchot, N; Brisson, H; Brossier, F; Chastre, J; Combes, A; Jarlier, V; Lu, Q; Luyt, CE; Micaelo, M; Rouby, JJ; Trouillet, JL | 1 |
| Ahmed, SS; Alp, E; Demiraslan, H; Dinc, G; Doganay, M; Elmali, F; Metan, G | 1 |
| Ogbolu, DO; Webber, MA | 1 |
| Cannon, JP; Clark, NM; Grim, SA; Lee, TA; Setlak, P | 1 |
| Igarashi, Y; Inui, K; Ohara, H; Ryozawa, S; Tazuma, S; Tsuyuguchi, T | 1 |
| Bonomo, RA; Cline, M; Cober, E; Conlan, S; Evans, S; Fowler, VG; Fox, J; Hall, GS; Hanrahan, J; Jacobs, MR; Kalayjian, RC; Kaye, KS; Mason, P; Perez, F; Richter, SS; Rudin, SD; Salata, RA; Segre, JA; van Duin, D; Webber, R; Ziegler, J | 1 |
| Arslan, U; Kus, H; Tuncer, I; Turk Dagi, H | 1 |
| Costa, SF; Dos Santos, LC; Fu, L; Guimaraes, T; Leite, G; Levin, AS; Ramos, J; Rizek, C; Rossi, F | 1 |
| Gu, B; Mei, Y; Wen, Y; Xia, W; Zhang, X | 1 |
| Ball, G; Fajardo, A; Filloux, A; Hernando-Amado, S; Martinez, JL; Oliver, A | 1 |
| Bishai, WR; Guo, H; Kubler, A; Lun, S; Maiga, MC; Miranda, D; Pelly, S; Winglee, K | 1 |
| Chiu, CH; Kuo, AJ; Lee, MH; Liu, TP; Shu, JC; Su, IN; Su, LH; Wu, TL | 1 |
| Egea, P; Fernández-Cuenca, F; Galán-Sánchez, F; Guerrero-Lozano, I; Pascual, Á; Rodríguez-Iglesias, M | 1 |
| Chen, Z; Li, L; Sun, Z; Tian, L; Wang, Y; Yan, S; Zhang, B; Zhu, X | 1 |
| Abe, J; Fujita, A; Hino, M; Hirose, A; Kakeya, H; Kaneko, Y; Nakaie, K; Nakamura, Y; Okada, Y; Takizawa, E; Yamada, K | 1 |
| Alcántar-Curiel, MD; Fernández-Vázquez, JL; García-Torres, LF; Gayosso-Vázquez, C; Giono-Cerezo, S; González-Chávez, MI; Jarillo-Quijada, MD; Morfín-Otero, R; Rodríguez-Noriega, E; Santos-Preciado, JI | 1 |
| Ahn, S; Han, WD; Kim, ES; Kim, HB; Kim, NH; Kim, TS; Park, KU; Seo, HK; Shin, MJ; Song, KH; Yoo, JS | 1 |
| Cheng, C; Rui, Y; Sun, J; Zheng, F | 1 |
| Bai, KJ; Chang, FY; Chen, RJ; Chen, YH; Chen, YS; Hsu, CW; Hsueh, PR; Jean, SS; Ko, WC; Lee, WS; Liao, CH; Liu, CY; Liu, JW; Lu, MC; Wu, JJ; Yu, KW | 1 |
| Dong, D; Huang, L; Huang, S; Huang, Y; Li, H; Liu, W; Tong, Y; Wang, X; Wei, X; Yan, X; Yang, Z; Yuan, J; Zhao, X; Zou, D | 1 |
| Decosterd, LA; Eggimann, P; Fournier, A; Marchetti, O; Pagani, JL; Pannatier, A; Que, YA; Revelly, JP; Voirol, P | 1 |
| Adams-Sapper, S; Chen, K; Donzelli, GF; Justo da Silva, LH; Lal, M; Moreira, BM; Nolen, S; Riley, LW | 1 |
| Amicosante, G; Bottoni, C; Celenza, G; Colapietro, M; Compagnoni, C; Marcoccia, F; Maturo, MG; Perilli, M; Sabatini, A; Segatore, B | 1 |
| Chuang, YC; Ku, YH; Lee, MF; Tang, HJ; Yu, WL | 1 |
| Chia, JH; Hsu, PC; Kuo, AJ; Lee, CH; Lee, MH; Su, TY; Ye, JJ | 1 |
| Al-Agamy, MH; Al-Ahdal, MN; Al-Qahtani, AA; Forbes, KJ; Ismail, MA; Lopes, BS; Shibl, AM | 1 |
| Bauernfeind, A; Schneider, I | 1 |
| Dinghong, M; Fei, G; Guanghua, G; Guohui, L; Jianhua, Z; Nianyun, W; Xili, Y; Yue, L | 1 |
| Balasubramanian, D; Mathee, K; Silver, LL; Zincke, D | 1 |
| Srinivas, NR | 1 |
| Jeon, H; Kang, HY; Kim, BR; Kim, CH; Lee, JC; Lee, SH; Lee, YC | 1 |
| Nilsakul, J; Panomket, P; Panya, M; Thirat, S; Wanram, S | 1 |
| Centis, R; D'Ambrosio, L; Dore, S; Esposito, S; Migliori, GB; Sotgiu, G; Spanevello, A; Tiberi, S | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Guitton, C; Jacqueline, C; Maitte, A; Potel, G | 1 |
| Aydın, F; Bayramoğlu, G; Gençoğlu Özgür, Ç; Kılıç, AO; Uluçam, G | 1 |
| Aktaş, Z; Akyön, Y; Aşçı Toraman, Z; Ay, S; Ayaş, R; Aydemir, Ş; Aydın, F; Bakıcı, Z; Bayramoğlu, G; Baysallar, M; Büyüktaş, A; Çağatay, M; Çakar, A; Çelik, C; Çöplü, N; Dündar, D; Erçal, BD; Güdücüoğlu, H; Gülay, Z; Günaydın, M; Gür, D; Hasdemir, U; Karatuna, O; Kayacan, Ç; Kılıç, A; Kılıç, H; Öğünç, D; Özhak Baysan, B; Parlak, M; Tünger, A; Yanık, K; Zer, Y | 1 |
| Mirza, IA; Wali, N | 1 |
| Hu, Q; Hu, Y; Lin, X; Lv, H; Xu, X; Zhang, R | 1 |
| Arakawa, Y; Jin, W; Kimura, K; Kurosaki, H; Mori, S; Wachino, J; Yamaguchi, Y | 1 |
| Abdollahi, A; Aliramezani, A; Boroumand, MA; Douraghi, M; Ghalavand, Z; Ghourchian, S; Mohammadzadeh, M; Nateghi Rostami, M; Rahbar, M; Zeraati, H | 1 |
| Chang, FY; Chen, TL; Chiu, CH; Chuang, MF; Kuo, SC; Lee, YT; Lin, JC; Wang, YC; Yang, YS | 1 |
| Chanawong, A; Charoensri, N; Lulitanond, A; Piyapatthanakul, S; Srisrattakarn, A; Supajeen, A; Wilailuckana, C; Wonglakorn, L | 1 |
| Caro-Vega, JM; García-Quintanilla, M; McConnell, MJ; Moreno-Martínez, P; Pachón, J; Pulido, MR | 1 |
| Aubry, A; Chastre, J; Crandon, JL; Luyt, CE; Nicolau, DP | 1 |
| Burgers, PC; Dekker, LJ; Goessens, WH; Kostzrewa, M; Luider, TM; Monteferrante, CG; Peer, M; Sparbier, K; Sultan, S; Ten Kate, MT | 1 |
| Al-Bayssari, C; Bakour, S; Bentakouk, MC; Boutefnouchet, N; Djahoudi, A; Mellouk, FZ; Meradji, S; Rolain, JM; Zouyed, F | 1 |
| Arai, K; Kashiwa, M; Nagano, N; Saito, R; Yamada, K | 1 |
| Al-Masaudi, S; Elawady, S; Elsherif, R; Harakeh, S; Ismail, D; Jastaniah, S; Karrouf, G | 1 |
| Devechio, BB; Moretto, JA; Pitondo-Silva, A; Stehling, EG | 1 |
| Dinic, M; Kocic, B; Mitic, R; Mladenovic-Antic, S; Petrovic, J; Randjelovic, G; Velickovic-Radovanovic, R | 1 |
| Hsieh, PF; Hsu, CR; Lin, TL; Pan, YJ; Wang, JT; Wu, MC | 1 |
| Hu, YF; Liu, CP; Shih, SC; Wang, NY | 1 |
| Boyanova, L; Kaneva, R; Markovska, R; Mitev, V; Mitov, I; Pencheva, D; Stankova, P; Stoeva, T | 1 |
| Hackel, MA; Hoban, DJ; Karlowsky, JA; Lob, SH; Sahm, DF | 1 |
| Bao, CM; Chen, FH; Chen, SM; Cui, EB; Huang, J; Li, T; Liu, X; Ning, NZ; Qu, F; Wang, H; Zhang, JL | 1 |
| Abdeltwab, NM; El-Domany, RA; El-Magd, MA; Emara, M; Moustafa, WH | 1 |
| Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
| Alp, E; Badal, R; Gulay, Z; Koksal, I; Korten, V; Lob, S; Mete, B; Mulazimoglu, L; Oguz, VA; Tabak, F; Unal, S; Yilmaz, G; Zarakolu, P | 1 |
| Ajao, AO; Albrecht, JS; Furuno, JP; Harris, AD; Johnson, JK; Pineles, LL; Robinson, GL; Thom, KA; Zhao, L | 1 |
| Baker, S; Duong, HHT; Nga, TVT; Tuan Anh, N; Tuan, HM; Tuan, NS; Vinh Chau, NV; Y, DM | 1 |
| Livermore, DM; Mushtaq, S; Vickers, A; Woodford, N | 1 |
| Azizi, E; Bajrami, R; Kurti, A; Lila, G; Mulliqi-Osmani, G; Raka, L | 1 |
| D'Arcy, S; Doumith, M; Findlay, J; Hopkins, KL; Howe, R; Mather, B; Meunier, D; Mustafa, N; Pike, R; Woodford, N; Wootton, M | 1 |
| Chudejova, K; Hrabak, J; Papagiannitsis, CC; Rotova, V; Skalova, A | 1 |
| Shaaban, MI; Shaker, MA | 1 |
| Bhamidimarri, SP; Soundararajan, G; Winterhalter, M | 1 |
| Fakhar, Z; Govender, T; Honarparvar, B; Kruger, HG; Lamichhane, G; Maguire, GEM; Walker, RC | 1 |
| Bai, C; Huang, Y; Li, P; Liu, H; Liu, Y; Niu, W; Yin, X; Yu, L; Yuan, J; Yuan, X; Zheng, J; Zou, D | 1 |
| Li, Y; Liu, J; Liu, XJ; Lyu, Y; Xue, F | 1 |
| Boudawara, T; Daoud, S; Kallel, R; Ksouda, K; Sahnoun, Z; Tahri, A; Zeghal, KM | 1 |
| Aitha, M; Bonomo, RA; Crowder, MW; González, MM; Lisa, MN; Llarrull, LI; Moreno, DM; Palacios, AR; Spencer, J; Tierney, DL; Vila, AJ | 1 |
| Huang, J; Li, J; Liu, Q; Lu, T; Ren, J; Wang, G; Wang, Z; Wu, J; Wu, X | 1 |
| Abdallah, M; Alharthy, A; Alodat, M; Amirah, MF; Badawi, M; Mady, AF; Rasheed, A | 1 |
| Lewis, S; Opene, BNA; Simner, PJ; Tamma, PD; Wang, R | 1 |
| Auzou, M; Castelain, S; Cattoir, V; Choquet, M; Decroix, V; Guiheneuf, R; Pluquet, E | 1 |
| Bush, K; Kashikar, A; Zhang, Y | 1 |
| Agüera, A; Bertakis, Y; Brebou, C; Martínez-Piernas, AB; Reina, AC; Sánchez Pérez, JA; Xekoukoulotakis, NP | 1 |
| Cayô, R; da Cruz, JB; Fehlberg, LCC; Gales, AC; Martins, WMBS; Narciso, AC; Ramos, PL; Santos, SV | 1 |
| Bonomo, RA; Harper, TM; June, CM; Leonard, DA; Powers, RA; Taracila, MA | 1 |
| Akamatsu, N; Hasegawa, H; Kaku, N; Kawamoto, Y; Kosai, K; Matsuda, J; Morinaga, Y; Uno, N; Yamakawa, H; Yanagihara, K | 1 |
| Feng, H; Fleming, J; Liu, W; Liu, X; Wang, DC; Wang, S | 1 |
| Baumgardner, DJ; Kram, JJ; Patel, K | 1 |
| Arlet, G; Boutiba-Ben Boubaker, I; Ferjani, S; Fernandez Martinez, M; Genel, N; Hammami, S; Hamzaoui, Z; Harbaoui, S; Maamar, E; Martinez-Martinez, L; Ocampo-Sosa, A; Saidani, M; Slim, A | 1 |
| Nakashima, H; Okamura, N; Takemura, H; Terakubo, S | 1 |
| Chang, KC; Chen, HA; Chin, YC; Chung, CY; Hsu, KH; Hu, A; Huang, SS; Liu, BR; Peng, WP; Soo, PC; Yeh, CH | 1 |
| Kim, YA; Park, YS | 1 |
| Barguellil, F; Ben Helal, R; Ben Moussa, M; Chedly, M; Dziri, R; El Asli, MS; Klibi, N | 1 |
| Aubry, A; Bréchot, N; Brossier, F; Jarlier, V; Lu, Q; Luyt, CE; Micaëlo, M; Monsel, A | 1 |
| Antachopoulos, C; Karampatakis, T; Roilides, E; Tsakris, A | 1 |
| Ali, A; Gupta, D; Khan, AU; Sharma, A; Srivastava, G | 1 |
| Avril, C; Belmonte, O; Benoit-Cattin, T; Bertrand, X; Bonnin, RA; Cholley, P; de Montera, AM; Dortet, L; Filleul, L; Hocquet, D; Jaffar-Bandjee, MC; Leclaire, A; Lugagne, N; Martak, D; Miltgen, G; Naas, T; Roquebert, B; Subiros, M; Thouverez, M; Traversier, N | 1 |
| Barth, AL; Martins, AF; Nunes, LS; Wilhelm, CM | 1 |
| Hall, RM; Nigro, SJ | 1 |
| Ishibashi, N; Ito, A; Ito-Horiyama, T; Nishikawa, T; Ota, M; Sato, T; Tsuji, M; Yamano, Y | 1 |
| Feng, J; Jia, R; Ju, Y; Li, J; Tang, N; Tian, J; Zhang, G | 1 |
| Hu, L; Palzkill, T; Prasad, BVV; Sankaran, B; Sun, Z | 1 |
| Gatermann, SG; Höfken, LM; Kaase, M; Lange, F; Pfennigwerth, N | 1 |
| Fujita, J; Kirikae, T; Kuwahara-Arai, K; Maeda, S; Mya, S; Nakasone, I; Sekiguchi, JI; Tada, T; Tin, HH; Tome, T; Uechi, K; Yanagisawa, I; Zan, KN | 1 |
| Kuroda, M; Matsui, M; Segawa, T; Sekizuka, T; Shibayama, K; Suzuki, S | 1 |
| Bocharova, Y; Chebotar, IV; Mayanskiy, NA; Savinova, T; Shagin, DA; Shelenkov, AA | 1 |
| Bhattacharjee, A; Bhowmik, D; Chakravarty, A; Chanda, DD; Chetri, S; Nath, K; Singha, M | 1 |
| Abbas, HA; Goda, RM; Kadry, AA; Shaker, GH | 1 |
| Al-Bustan, SA; Alkhudhairy, MK; Alshadeedi, SMJ; Ghasemian, A; Mahmood, SS | 1 |
| Baillon-Plot, N; Charbonneau, C; Di Virgilio, R; Falcone, M; Kongnakorn, T; Tichy, E; Wagenlehner, F | 1 |
| Azougagh, K; Barbier, F; Boulain, T; Boutrot, M; Guinard, J | 1 |
| Smith, CA; Stewart, NK; Toth, M; Vakulenko, SB | 1 |
| Nishiura, H; Terahara, F | 1 |
| Ghalavand, Z; Kadkhoda, H; Kodori, M; Maleki, DT; Mohammadzadeh, M; Salehi, B | 1 |
| Antonelli, A; Camarlinghi, G; Coppi, M; Giani, T; Mattei, R; Nardone, M; Parisio, EM; Riccobono, E; Rossolini, GM | 1 |
| Agüera, A; Bertakis, Y; Cabrera-Reina, A; Martínez-Piernas, AB; Sánchez Pérez, JA; Xekoukoulotakis, NP | 1 |
| Anandan, S; Bhattacharya, S; Deotale, V; Kanthan, K; Kapil, A; Mathur, P; Ms, DP; Ohri, VC; Ray, P; Sistla, S; Veeraraghavan, B; Vijayabaskar, S; Vijayakumar, S; Walia, K; Wattal, C | 1 |
| Caroline, C; Chien-Boon Lye, D; Choon-Kiat Tan, N; Ding, YY; Hsien-Xiong Lee, R; Lim, JP; Neo, HY; Pei-Ying Ho, E; Tan, KT; Wei-Han Ng, D | 1 |
| Das, S; Ihssen, J; Shabat, D; Spitz, U; Wick, L | 1 |
| Hu, J; Huang, G; Liang, W; Liu, X; Shang, Y; Shi, H; Wang, Y; Yang, L; Zhang, Y; Zhao, C; Zhu, W; Zhuang, W | 1 |
| Cury, AP; Duarte, AJDS; Girardello, R; Rossi, F | 1 |
| Berthault, C; Bonnin, RA; Dortet, L; Iorga, BI; Marchini, L; Naas, T; Oueslati, S; Retailleau, P | 1 |
| Jing, X; Liu, R; Min, X; Wan, D; Wu, T; Zeng, J; Zhang, X; Zhou, H | 1 |
| Gatermann, SG; Körber-Irrgang, B; Korte-Berwanger, M; Kresken, M; Pfennigwerth, N; Seifert, H | 1 |
| Ali, A; Khan, A; Khan, AU; Kumar, R | 1 |
| Horikoshi, Y; Igarashi, T; Kasai, M; Kinoshita, N; Komura, M; Miyairi, I; Saitoh, J; Shinjoh, M; Shoji, K; Sugahara, Y; Watanabe, Y | 1 |
| Blétard, S; Di Costanzo, S; Esposito, R; Galleni, M; Kerff, F; Mercuri, PS; Perilli, M | 1 |
| Sfeir, MM | 1 |
| Cao, J; Dhanasekaran, V; Fang, R; Li, J; Lithgow, T; Liu, H; Perlaza-Jiménez, L; Tian, X; Wang, C; Wang, Q; Zhao, Y; Zheng, X; Zhou, T | 1 |
| Bhattacharyya, I; Pal, A; Tripathi, A | 1 |
| Cha, YJ; Cho, H; Choi, JE; Heo, W; Kim, JO; Lee, H; Park, YJ; Yoo, IY | 1 |
| Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A | 1 |
| Allison, N; Crisostomo, C; Lynch, B; Padilla, M; Quach-Cu, J; Reinke, RA | 1 |
| Hirabayashi, A; Kajihara, T; Shibayama, K; Sugai, M; Yahara, K | 1 |
| Bian, W; Chen, W; Gu, X; Liu, Y; Qin, Y; Wang, S; Zhao, G | 1 |
| Dai, Y; Ma, H; Nangia, S; Ren, D; Vora, SR; Welsch, TA; Wu, M | 1 |
| Chahine, EB; Karaoui, LR; Mansour, H; Ouweini, AEL | 1 |
| Duan, R; Fan, Y; Huang, Z; Jing, H; Lv, D; Qin, S; Shi, X; Stirling, K; Wang, H; Wang, J; Wang, X; Zhang, L | 1 |
| Hsieh, YJ; Kao, LT; Lian, SH; Lin, IL; Liu, GH; Lu, PL; Tseng, SP; Wang, HY; Wang, LC; Yang, TY | 1 |
| Banerjee, T; Barman, H; Das, A; Kumar, A; Sharma, S; Yadav, G | 1 |
| Borghi, M; Devereux, M; Ferreira Ventura, R; FerreiraNunes, AP; McCann, M; Pinto Schuenck, R; Souza Dos Santos, AL; Vianez Peregrino, I | 1 |
| Bragantini, D; Carrara, E; Cattaneo, P; Chiamenti, M; Ellis, S; Franceschi, F; Giske, CG; Lodise, T; Menchinelli, G; Piddock, LJV; Righi, E; Sanguinetti, M; Savoldi, A; Scudeller, L; Tacconelli, E | 1 |
| Chen, TL; Huang, TW; Kuo, SC; Lee, YT; Lin, PY; Liu, CP; Liu, IF; Liu, YM; Wang, FD; Wang, YC; Yang, YS | 1 |
| Cai, J; Cui, W; Huang, J; Qian, Z; Song, F; Zhang, G; Zhang, K; Zheng, C; Zhou, F; Zhou, H | 1 |
| Horwich-Scholefield, S; Huang, S; Lloyd, T; Pandori, M; Varghese, V; Yette, E | 1 |
| Chitsombat, K; Chomnawang, MT; Kanathum, P; Khuntayaporn, P; Thirapanmethee, K | 1 |
| Arend, LNVS; Bail, L; Ito, CAS; Nogueira, KDS; Tuon, FF | 1 |
| Pazin-Filho, A; Romo-Castillo, HF | 1 |
| Chang, H; Liu, CP; Sun, FJ; Wang, NY; Wu, AY | 1 |
| Aitken, SL; Gerges, BZ; Prince, RA; Raad, II; Reitzel, R; Rolston, KVI; Shelburne, SA | 1 |
| Liu, Q; Shi, S; Xu, M; Yao, Z; Ye, J; Zhang, X; Zhang, Y; Zhou, B; Zhou, C; Zhou, T | 1 |
| Berényi, Á; Burián, K; Fehér, T; Lang, U; Nagy, E; Nagy, I; Schumacher, U; Sóki, J | 1 |
| Becerra-Aparicio, F; Fuchs, F; Higgins, PG; Seifert, H; Xanthopoulou, K | 1 |
| Hussein Al-Kakei, SN; Hussein, NH; Mohammed Kareem, S; Taha, BM | 1 |
| Acioly de Omena, IC; Alvino, V; Bastos, MLA; Lopes da Silva, AL; Oliveira de Araujo, JF; Todaro, AR | 1 |
| Chen, L; Chen, T; Fang, R; Liao, W; Xu, C; Zhang, S; Zhou, C; Zhou, T | 1 |
| Cui, L; Li, Y; Wang, Q; Xue, F; Zheng, B | 1 |
| Chen, H; Li, N; Liang, W; Wang, F; Wang, L | 1 |
| Lodise, TP; O'Donnell, JN | 1 |
| Aseffa, A; Asrat, D; Jass, J; Mihret, A; Olsson, PE; Woldeamanuel, Y; Yitayew, B | 1 |
| Birgy, A; Bonacorsi, S; Courroux, C; Danjean, M; Gits-Muselli, M; Hobson, CA; Monjault, A | 1 |
| Cohen, RD; Martin, GE; Sherer, EC; Wang, X | 1 |
| Chibabhai, V; Nana, T; Perovic, O | 1 |
| Bezruk, VV; Bulyk, TS; Buriak, OH; Godovanets, OS; Honcharuk, LM; Hresko, MD; Hresko, MM; Makarova, OV; Pervozvanska, OI; Rynzhuk, LV; Sheremet, MI; Shkrobanets, ID; Velia, MI; Voytkevich, NI; Yurkiv, OI; Yurniuk, SV | 1 |
| Capalash, N; Kashyap, S; Sharma, P; Sidhu, H | 1 |
| Akeda, Y; Hamada, S; Iida, T; Matsumoto, Y; Motooka, D; Sakamoto, N; Sugawara, Y | 1 |
| Al-Madboly, LA | 1 |
| Findlay, J; Nordmann, P; Poirel, L; Rens, C | 1 |
| Kurisu, G; Nakano, R; Sakai, H; Tanaka, H; Yamamoto, K; Yano, H | 1 |
| Haines, RR; Hammer, KA; Putsathit, P; Tai, AS | 1 |
| Abdulhemid Said, L; Muhsin, EA; Sajid Al-Jubori, S | 1 |
| Fekete, M; Göbölös, B; Háhn, J; Jiang, D; Kaszab, E; Kriszt, B; Szabó, I; Szoboszlay, S; Tóth, G; Urbányi, B | 1 |
| Jarjees, KK; Jarjees, RK; Qader, GM | 1 |
| Ishaq, M; Zahra, N; Zeshan, B | 1 |
| Palzkill, T; Song, Z; Tao, P; Tian, H; Yin, C | 1 |
| Bassetti, M; Bini, L; Giacobbe, DR; Magnè, F; Vena, A | 1 |
| Dargahi, Z; Etemad, A; Ghasemian, E; Hashemian, M; Kaviar, VH; Lohrasbi, A; Saadh, MJ | 1 |
| Alzahrani, FM; Alzahrani, KJ; Amoa-Owusu, F; Bannah, V; Dayie, NTKD; Donkor, ES; Dwomoh, FP; Egyir, B; Halawani, IF; Kotey, FCN; Osei, MM | 1 |
| Fang, SB; Fujisawa, M; Kado, M; Maeda, K; Onishi, R; Osawa, K; Shigemura, K; Tanimoto, H; Yang, YM | 1 |
| Fu, C; Kong, J; Qian, C; Tang, M; Xu, C; Ye, J; Zeng, W; Zhang, X; Zhou, T | 1 |
| Barmudeh, S; Batignani, V; Cirillo, DM; Ghodousi, A; Haeili, M; Kafil, HS; Omrani, M; Zeinalzadeh, N | 1 |
| Deng, Y; Huang, W; Li, J; Qiao, F; Zhang, W; Zhu, S; Zong, Z | 1 |
| George Priya Doss, C; Gopikrishnan, M | 1 |
| König, E; Zollner-Schwetz, I | 1 |
| Akcam, FZ; Cetin, ES; Gonen, I; Kaya, O; Ozturk, T; Temel, EN; Unal, O | 1 |
| Abdurahim, SA; Alameen, AA; Aloufi, AS; Elsayim, R; Eltayb, WA; Modafer, Y | 1 |
| Shamsuzzaman, SM; Sonia, SJ; Uddin, KH | 1 |
| Carvalhaes, CG; Castanheira, M; Duncan, L; Kimbrough, JH; Mendes, RE; Sader, HS | 1 |
| Chan, EWC; Chen, D; Chen, E; Chen, K; Chen, S; Chen, W; Guo, J; Jelsbak, L; Wang, J; Xie, L; Xie, M; Zhao, Y | 1 |
| Chau, RWY; Chen, WT; DeRyke, CA; Ip, M; Karlowsky, JA; Khan, TK; Leung, SWM; Lob, SH; Motyl, MR; Sahm, DF; Seto, WH; Wong, QW; Woo, PCY; Young, K | 1 |
| Ahmed Al-Bayati, M; Kareem Musafer, H; Nabeeh Jaafar, F | 1 |
| Gu, Y; Hu, D; Hu, M; Liang, R; Wang, D; Wang, M; Zhu, M | 1 |
| Hsueh, PR; Ko, WC; Lee, YL | 1 |
| Leng, T; Li, XL; Liao, QF; Shu, L; Wu, CY; Xiao, YL; Xie, Y; Zhang, WL | 1 |
| Jin, Z; Meng, L; Sha, L; Wu, L; Wu, Z; Yang, F; Yu, C; Yu, J; Zhang, H; Zhao, Q | 1 |
| DeRyke, CA; Hackel, M; Hilbert, DW; Motyl, M; Young, K | 1 |
| Bölükbaş, A; Çadirci, Ö; Gücükoğlu, A; Uyanik, T | 1 |
| Lukovic, B; Petrovic, I; Zornic, S | 1 |
| Ahmed, A; Chryssanthou, E; Davies Forsman, L; Fröberg, G | 1 |
| Bouguessa, A; Debabza, M; Dziri, R; Klibi, N; Mechai, A; Ouzari, HI | 1 |
| Gill, CM; Lee, SY; Nicolau, DP | 1 |
| El Chaar, M; Jisr, T; Moussa, J; Nassour, E; Tahan, E; Tokajian, S | 1 |
| Akrami, S; Al-Dahmoshi, HOM; Al-Khafaji, NSK; Bannazadeh Baghi, H; Jafari-Sales, A; Judi, HK; Nasiri, R; Sadeghi Deylamdeh, Z; Saki, M; Shariat, A | 1 |
| Alharbi, N; Kadaikunnan, S | 1 |
28 review(s) available for carbapenems and imipenem, anhydrous
| Article | Year |
|---|---|
[Carbapenems in pediatrics].
Topics: Carbapenems; Child; Child, Preschool; Humans; Imipenem; Infant; Infant, Newborn; Meningitis, Bacterial; Meropenem; Thienamycins | 1996 |
[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract].
Topics: Adult; Aged; Carbapenems; Chi-Square Distribution; Cilastatin; Cross Infection; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Protease Inhibitors; Thienamycins; Urinary Tract Infections | 1995 |
Pharmacokinetic determinants of carbapenem therapy in neonates and children.
Topics: Area Under Curve; Carbapenems; Child; Child, Preschool; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Infant; Infant, Newborn; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1996 |
Neurotoxicity of carbapenem antibacterials.
Topics: Animals; Carbapenems; Child; Cilastatin; Humans; Imipenem; Meropenem; Receptors, GABA; Seizures; Thienamycins | 1996 |
Acquired carbapenemases.
Topics: Acinetobacter; Bacillus cereus; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cell Cycle Proteins; Endopeptidases; Enterobacter cloacae; Fungal Proteins; Imipenem; Intracellular Signaling Peptides and Proteins; Meropenem; Protein Kinases; Protein Serine-Threonine Kinases; Pseudomonas aeruginosa; Saccharomyces cerevisiae Proteins; Serratia marcescens; Thienamycins | 1997 |
Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections.
Topics: Abdomen; Bacterial Infections; Carbapenems; Drug Therapy, Combination; Humans; Imipenem; Meropenem; Randomized Controlled Trials as Topic; Thienamycins | 1997 |
[The role of carbapenems in the treatment of nosocomial infection].
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Cross Infection; Drug Therapy, Combination; Humans; Imipenem; Meningitis, Bacterial; Meropenem; Pneumonia, Bacterial; Skin Diseases, Infectious; Thienamycins | 1997 |
[Carbapenems in pediatric practice].
Topics: Adolescent; Bacterial Infections; Carbapenems; Child; Child, Preschool; Clinical Trials as Topic; Humans; Imipenem; Infant; Infant, Newborn; Meropenem; Postoperative Complications; Thienamycins | 2001 |
Appropriate use of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Cilastatin; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Ertapenem; Humans; Imipenem; Lactams; Meropenem; Patient Selection; Pneumonia, Bacterial; Practice Patterns, Physicians'; Protease Inhibitors; South Africa; Surgical Wound Infection; Thienamycins; Urinary Tract Infections | 2004 |
[Antibiotic prophylaxis in acute pancreatitis--is the evidence good enough?].
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Carbapenems; Evidence-Based Medicine; Humans; Imipenem; Pancreatitis, Acute Necrotizing; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed | 2005 |
Meta-analysis of prophylactic parenteral antibiotic use in acute necrotizing pancreatitis.
Topics: Antibiotic Prophylaxis; Carbapenems; Data Interpretation, Statistical; Evidence-Based Medicine; Humans; Imipenem; Incidence; Injections, Intravenous; Necrosis; Odds Ratio; Pancreas; Pancreatitis, Acute Necrotizing; Pefloxacin; Prevalence; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sepsis; Time Factors; Tomography, X-Ray Computed | 2007 |
Comparative review of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Thienamycins | 2007 |
Carbapenems in the USA: focus on doripenem.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Structure-Activity Relationship; Thienamycins; United States | 2007 |
Carbapenems: a potent class of antibiotics.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Molecular Structure; Structure-Activity Relationship; Thienamycins | 2008 |
Parenteral carbapenems.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Humans; Imipenem; Infusions, Parenteral; Meropenem; Thienamycins | 2008 |
The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cross Infection; Doripenem; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Patient Selection; Pneumonia, Bacterial; Respiratory Tract Infections; Severity of Illness Index; Thienamycins; Treatment Outcome | 2008 |
Carbapenems: past, present, and future.
Topics: Anti-Bacterial Agents; beta-Alanine; beta-Lactams; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Ertapenem; Humans; Imipenem; Thienamycins | 2011 |
Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Clinical Trials as Topic; Databases, Bibliographic; Doripenem; Drug Combinations; Female; Humans; Imipenem; Levofloxacin; Male; Research Design; Treatment Outcome; Urinary Tract Infections | 2013 |
The risk of seizures among the carbapenems: a meta-analysis.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Child; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Ertapenem; Humans; Imipenem; Meropenem; Risk; Seizures; Thienamycins | 2014 |
Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Topics: Antitubercular Agents; beta-Lactams; Carbapenems; Clinical Studies as Topic; Ertapenem; Extensively Drug-Resistant Tuberculosis; Humans; Imipenem; Meropenem; Thienamycins; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
Epidemiology and treatment of antimicrobialresistant gram-negative bacteria in Korea.
Topics: Acinetobacter baumannii; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Republic of Korea; Retrospective Studies | 2018 |
Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Greece; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Epidemiology; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2018 |
The role of new antimicrobials for Gram-negative infections in daily clinical practice.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines | 2020 |
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymyxins; Rifampin; Tazobactam; Tobramycin | 2021 |
New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Humans; Imipenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa | 2022 |
New antibiotics for Gram-negative pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Imipenem; Pneumonia, Bacterial | 2022 |
The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
Treatment options for multidrug-resistant Gram-negatives in urinary tract infections.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Gram-Negative Bacterial Infections; Humans; Imipenem; Urinary Tract Infections | 2023 |
21 trial(s) available for carbapenems and imipenem, anhydrous
| Article | Year |
|---|---|
Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems.
Topics: Adult; Aged; Bacterial Infections; Carbapenems; Cefmetazole; Cefoperazone; Cefotetan; Cefoxitin; Cephalosporins; Drug Combinations; Drug Resistance, Microbial; Escherichia coli Infections; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Prospective Studies; Remission Induction; Skin Diseases, Infectious; Staphylococcal Infections; Streptococcal Infections; Thienamycins | 1991 |
Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Chromatography, High Pressure Liquid; Cilastatin; Cilastatin, Imipenem Drug Combination; Dipeptidases; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Humans; Imipenem; Kidney; Lactams; Male; Reference Values | 1990 |
Immune response in patients with intra-abdominal infections treated with carbapenems.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Antibodies, Bacterial; Bacteria, Aerobic; Bacteria, Anaerobic; Carbapenems; Cilastatin; Fluorescent Antibody Technique; Humans; Imipenem; Injections, Intravenous; Meropenem; Middle Aged; Thienamycins | 1994 |
Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group.
Topics: Bacterial Infections; Carbapenems; Ceftazidime; Cilastatin; Humans; Imipenem; Injections, Intramuscular; Meropenem; Respiratory Tract Infections; Thienamycins; Treatment Outcome; Urinary Tract Infections | 1995 |
Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group.
Topics: Bacterial Infections; Bronchitis; Carbapenems; Cilastatin; Drug Therapy, Combination; Drug Tolerance; Hospitalization; Humans; Imipenem; Lung Diseases, Obstructive; Meropenem; Prospective Studies; Thienamycins; Treatment Outcome | 1995 |
Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
Topics: Abdomen; Adolescent; Adult; Aged; Bacterial Infections; Carbapenems; Cilastatin; Drug Therapy, Combination; Humans; Imipenem; Injections, Intravenous; Meropenem; Middle Aged; Thienamycins; Treatment Outcome | 1995 |
[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract].
Topics: Adult; Aged; Carbapenems; Chi-Square Distribution; Cilastatin; Cross Infection; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Protease Inhibitors; Thienamycins; Urinary Tract Infections | 1995 |
Carbapenem resistance in Pseudomonas aeruginosa from cystic fibrosis patients.
Topics: Adolescent; Adult; beta-Lactamases; Carbapenems; Child; Child, Preschool; Cystic Fibrosis; Drug Resistance, Microbial; Evaluation Studies as Topic; Humans; Imipenem; Infant; Infant, Newborn; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Species Specificity; Thienamycins | 1996 |
Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Cross Infection; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Prospective Studies; Thienamycins | 1997 |
Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients.
Topics: Adolescent; Bacterial Infections; Bone Marrow Transplantation; Carbapenems; Child; Child, Preschool; Cilastatin; Drug Costs; Female; Humans; Imipenem; Male; Meropenem; Postoperative Complications; Prospective Studies; Protease Inhibitors; Thienamycins; Vomiting | 2002 |
Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Cilastatin; Cilastatin, Imipenem Drug Combination; Clarithromycin; Community-Acquired Infections; Costs and Cost Analysis; Drug Combinations; Drug Costs; Drug Therapy, Combination; Female; Hospitalization; Humans; Imipenem; Male; Meropenem; Pneumonia, Bacterial; Prospective Studies; Thienamycins; Treatment Outcome | 2002 |
[Investigation on administration method of carbapenems].
Topics: Adult; Aged; beta-Alanine; Body Temperature; C-Reactive Protein; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Administration Schedule; Drug Combinations; Female; Humans; Imipenem; Leukocyte Count; Meropenem; Middle Aged; Parametritis; Thienamycins | 2002 |
Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Imipenem; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Pilot Projects; Rifampin; Treatment Outcome | 2006 |
Impact of carbapenem administration on systemic endotoxemia in patients with severe sepsis and Gram-negative bacteremia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; C-Reactive Protein; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Endotoxemia; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Interleukin-6; Lipopolysaccharides; Male; Middle Aged; Pneumonia, Ventilator-Associated; Sepsis | 2006 |
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
Topics: Aged; Anti-Bacterial Agents; APACHE; Carbapenems; Doripenem; Female; Hospital Mortality; Humans; Imipenem; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Treatment Outcome | 2008 |
"The truth, if it exists, is in the details".
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Doripenem; Humans; Imipenem; Pneumonia, Ventilator-Associated; Severity of Illness Index; Treatment Outcome | 2008 |
Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Costs and Cost Analysis; Doripenem; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hospital Costs; Humans; Imipenem; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Pneumonia, Ventilator-Associated; Survival Rate; Treatment Outcome | 2008 |
A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cilastatin; Doripenem; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imipenem; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Ventilator-Associated; Young Adult | 2012 |
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Female; Humans; Imipenem; Intraabdominal Infections; Male; Meropenem; Ofloxacin; Pneumonia; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas Infections; Thienamycins | 2014 |
Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Body Temperature; C-Reactive Protein; Carbapenems; Cholangitis; Cholecystitis, Acute; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Female; Humans; Imipenem; Infusions, Intravenous; Male; Middle Aged; Treatment Outcome; Young Adult | 2015 |
484 other study(ies) available for carbapenems and imipenem, anhydrous
| Article | Year |
|---|---|
Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex.
Topics: Animals; Carbapenems; Chromatography, High Pressure Liquid; Dipeptidases; Humans; Imipenem; Kidney Cortex; Swine | 1992 |
In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp.
Topics: Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests; Nocardia; Thienamycins | 1992 |
Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic.
Topics: Animals; Carbapenems; Chromatography, High Pressure Liquid; Dipeptidases; Humans; Hydrolysis; Imipenem; In Vitro Techniques; Kidney; Kinetics; Macaca fascicularis; Spectrophotometry, Ultraviolet; Swine; Thienamycins | 1992 |
Comparative antibacterial activity of the penem ALP 201.
Topics: beta-Lactamases; Carbapenems; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Imipenem; Microbial Sensitivity Tests; Streptococcaceae | 1991 |
Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group.
Topics: Bacteroides fragilis; Carbapenems; Drug Evaluation, Preclinical; Imipenem; Kinetics; Meropenem; Microbial Sensitivity Tests; Thienamycins; Time Factors | 1991 |
In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.
Topics: Amikacin; Animals; Bacterial Infections; Bacteroides fragilis; Carbapenems; Ceftazidime; Cilastatin; Ciprofloxacin; Dipeptidases; Drug Therapy, Combination; Escherichia coli; Female; Imipenem; Klebsiella pneumoniae; Metronidazole; Mice; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Staphylococcus; Streptococcus; Thienamycins | 1991 |
Antibacterial activity of FCE 22101 against relatively resistant blood culture isolates.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Microbial; Enterobacteriaceae; Humans; Imipenem; Methicillin Resistance; Saudi Arabia; Staphylococcus aureus | 1991 |
Decreases of the susceptibility to low molecular weight beta-lactam antibiotics in imipenem-resistant Pseudomonas aeruginosa mutants: role of outer membrane protein D2 in their diffusion.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; beta-Lactams; Carbapenems; Diffusion; Drug Resistance, Microbial; Electrophoresis, Polyacrylamide Gel; Imipenem; Lactams; Liposomes; Microbial Sensitivity Tests; Molecular Weight; Permeability; Pseudomonas aeruginosa; Thienamycins | 1990 |
Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Hydrolysis; Imipenem; Isoelectric Focusing; Kinetics; Microbial Sensitivity Tests; Serratia marcescens; Spectrophotometry, Ultraviolet | 1990 |
In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.
Topics: Animals; Bacterial Proteins; beta-Lactamases; Carbapenems; Carrier Proteins; Ceftazidime; Dipeptidases; Gram-Negative Bacteria; Gram-Positive Bacteria; Hexosyltransferases; Hydrolysis; Imipenem; Kidney; Kinetics; Microbial Sensitivity Tests; Microscopy, Phase-Contrast; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Peptidyl Transferases; Protein Binding; Swine; Thienamycins | 1990 |
In vitro antibacterial activity and beta-lactamase stability of the new carbapenem LJC10,627.
Topics: Bacteria; beta-Lactamases; Carbapenems; Cefpirome; Ceftazidime; Cephalosporins; Humans; Imipenem; Molecular Structure; Thienamycins | 1990 |
Heterogeneity of beta-lactamase production in Pseudomonas maltophilia, a nosocomial pathogen.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Microbial; Enzyme Induction; Imipenem; Kinetics; Meropenem; Pseudomonas; Thienamycins | 1990 |
The postantibiotic effect of meropenem and imipenem on selected bacteria.
Topics: Bacteria; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests; Providencia; Pseudomonas aeruginosa; Serratia marcescens; Staphylococcus aureus; Thienamycins | 1989 |
In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.
Topics: Anti-Bacterial Agents; Bacteria; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Ceftazidime; Culture Media; Enterobacteriaceae; Germany, West; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Lactams; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 1989 |
Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
Topics: Bacterial Outer Membrane Proteins; beta-Lactamases; Carbapenems; Carbenicillin; Cell Membrane Permeability; DNA Transposable Elements; Drug Resistance, Microbial; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Genes, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1989 |
Evaluation of FCE 22101 in experimental meningitis caused by Escherichia coli and Streptococcus pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Blood Bactericidal Activity; Carbapenems; Ceftriaxone; Escherichia coli Infections; Imipenem; Meningitis; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Penicillins; Rabbits | 1989 |
Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
Topics: Bacteria; beta-Lactamases; Carbapenems; Ceftazidime; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Plasmids; Thienamycins | 1989 |
Interaction of meropenem with humoral and phagocytic defences.
Topics: Antibody Formation; Carbapenems; Escherichia coli; Imipenem; Macrophages; Meropenem; Microbial Sensitivity Tests; Neutrophils; Opsonin Proteins; Phagocytosis; Staphylococcus aureus; Thienamycins | 1989 |
Efficacy of FCE 22101 compared with imipenem and with gentamicin plus metronidazole in the treatment of experimental intra-abdominal infections in rats.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Gentamicins; Imipenem; Male; Metronidazole; Microbial Sensitivity Tests; Rats; Rats, Inbred Strains; Time Factors | 1989 |
In-vitro activity of the penem, FCE 22101, and tentative interpretive criteria for disc susceptibility tests.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Drug Resistance, Microbial; Imipenem; Microbial Sensitivity Tests | 1989 |
Activity of FCE 22101 against methicillin-resistant Staphylococcus aureus and affinity for penicillin binding proteins.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Carrier Proteins; Hexosyltransferases; Imipenem; Methicillin; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Penicillin Resistance; Penicillin-Binding Proteins; Peptidyl Transferases; Staphylococcus aureus | 1989 |
Comparative inhibitory and bactericidal activities of FCE 22101 against gram-positive cocci and anaerobes in vitro.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Carbapenems; Clostridium; Culture Media; Gram-Positive Bacteria; Imipenem; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus | 1989 |
In-vitro activity of FCE 22101 against respiratory tract pathogens with reference to production of beta-lactamases.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamases; Carbapenems; Ceftibuten; Cephalosporins; Imipenem; Microbial Sensitivity Tests; Respiratory Tract Infections | 1989 |
The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Clindamycin; Gram-Negative Anaerobic Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Meropenem; Metronidazole; Microbial Sensitivity Tests; Thienamycins | 1989 |
Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.
Topics: Bacterial Proteins; Carbapenems; Carrier Proteins; Cell Membrane Permeability; Culture Media; Drug Resistance, Microbial; Enterobacteriaceae; Gram-Negative Bacteria; Hexosyltransferases; Imipenem; Meropenem; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Peptidyl Transferases; Staphylococcus; Thienamycins | 1989 |
In-vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other beta-lactams, chloramphenicol and ciprofloxacin.
Topics: Ampicillin; Anti-Bacterial Agents; Carbapenems; Chloramphenicol; Ciprofloxacin; Culture Media; Haemophilus influenzae; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillin Resistance; Thienamycins | 1989 |
Meropenem: evidence of lack of proconvulsive tendency in mice.
Topics: Animals; Carbapenems; Cilastatin; Imipenem; Male; Meropenem; Mice; Seizures; Thienamycins | 1989 |
The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cephalosporins; Gram-Negative Bacteria; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Thienamycins | 1985 |
In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Ceftazidime; Imipenem; Microbial Sensitivity Tests; Quality Control | 1988 |
Activity of penems against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Microbial; Imipenem; Lactams; Methicillin; Microbial Sensitivity Tests; Staphylococcus aureus | 1988 |
Comparative neurotoxicity of benzylpenicillin, imipenem/cilastatin and FCE 22101, a new injectible penem.
Topics: Animals; Anti-Bacterial Agents; Brain; Carbapenems; Cilastatin; Drug Interactions; Electroencephalography; Imipenem; Penicillin G; Rabbits | 1988 |
Neurotoxicity of beta-lactam antibiotics. Experimental kinetic and neurophysiological studies.
Topics: Acute Kidney Injury; Animals; Anti-Bacterial Agents; Blood-Brain Barrier; Brain; Carbapenems; Cilastatin; Drug Interactions; Electroencephalography; Enterobacteriaceae Infections; Female; Hippocampus; Imipenem; Male; Meningitis; Penicillin G; Rabbits; Rats; Rats, Inbred Strains; Seizures; Thiopental; Tissue Distribution; Uremia | 1988 |
In-vitro activity of two new carbapenems FCE 22101 and CGP 31608 in comparison with imipenem.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Synergism; Hydrogen-Ion Concentration; Imipenem; Lactams; Microbial Sensitivity Tests; Thienamycins | 1987 |
Potential factors influencing carbapenem activity against Bacteroides fragilis group isolates.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacteroides fragilis; beta-Lactamases; Carbapenems; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1995 |
Are all carbapenems created equal?
Topics: beta-Lactam Resistance; Burkholderia cepacia; Carbapenems; Imipenem; Meropenem; Thienamycins | 1995 |
[New approaches in the use of antibiotics in the treatment of postoperative intra-abdominal infections].
Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Female; Humans; Imipenem; Male; Middle Aged; Postoperative Complications | 1995 |
In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity.
Topics: Carbapenems; Guanidines; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas; Thienamycins | 1995 |
Search for protein cross-reacting with OprD antibodies in Pseudomonas spp. and related species.
Topics: Animals; Antibodies; Bacterial Outer Membrane Proteins; Carbapenems; Cross Reactions; Drug Resistance, Microbial; Humans; Imipenem; Porins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Rabbits | 1994 |
Postantibiotic effects of three carbapenems on Pseudomonas aeruginosa in the presence of lysine.
Topics: Carbapenems; Imipenem; Lysine; Meropenem; Pseudomonas aeruginosa; Thienamycins | 1995 |
In vitro activity and killing effect of DX-8739, a new carbapenem, compared with those of meropenem and imipenem against multiresistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple; Imipenem; Meropenem; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Thienamycins | 1995 |
Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex.
Topics: Alanine; Animals; Carbapenems; Glycosuria, Renal; Imipenem; In Vitro Techniques; Kidney Cortex; Kidney Diseases; Male; Necrosis; Proteinuria; Rabbits; Thienamycins | 1994 |
In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity.
Topics: Anti-Bacterial Agents; Carbapenems; Ceftazidime; Dipeptidases; Drug Stability; Gram-Negative Bacteria; Gram-Positive Bacteria; Hydrolysis; Imipenem; Kidney; Meropenem; Microbial Sensitivity Tests; Pseudomonas; Thienamycins | 1993 |
Synthesis and antibacterial activity of new 2-substituted penems. I.
Topics: Anti-Bacterial Agents; Carbapenems; Imipenem; Microbial Sensitivity Tests; Pyridines; Structure-Activity Relationship | 1993 |
Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Cephalosporinase; Drug Resistance, Microbial; Humans; Hydrolysis; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 1993 |
BO-2727, meropenem and imipenem disc diffusion susceptibility testing criteria.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Diffusion; Imipenem; Meropenem; Microbial Sensitivity Tests; Predictive Value of Tests; Thienamycins | 1995 |
Outer membrane alterations in Pseudomonas aeruginosa after five-day exposure to quinolones and carbapenems.
Topics: Anti-Infective Agents; Bacterial Outer Membrane Proteins; Carbapenems; Cell Membrane; Ciprofloxacin; Fluoroquinolones; Imipenem; Lipopolysaccharides; Meropenem; Microbial Sensitivity Tests; Naphthyridines; Pseudomonas aeruginosa; Thienamycins; Time Factors | 1995 |
Effects of a beta-lactamase inhibitor, sulbactam, on the activity of carbapenems against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Drug Synergism; Enzyme Inhibitors; Imipenem; Meropenem; Pseudomonas aeruginosa; Sulbactam; Thienamycins | 1995 |
Lack of additive effect between mechanisms of resistance to carbapenems and other beta-lactam agents in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; beta-Lactamases; Blotting, Western; Carbapenems; Cephaloridine; Drug Resistance, Microbial; Drug Therapy, Combination; Imipenem; Isoelectric Focusing; Porins; Pseudomonas aeruginosa | 1995 |
Pneumococcal susceptibility to meropenem.
Topics: beta-Lactam Resistance; Carbapenems; Drug Resistance, Microbial; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillin Resistance; Streptococcus pneumoniae; Thienamycins | 1996 |
Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Dipeptidases; Drug Combinations; Drug Therapy, Combination; Half-Life; Imidazoles; Imipenem; Injections, Intravenous; Kidney; Macaca mulatta; Male; Methicillin Resistance; Pan troglodytes; Staphylococcus aureus | 1996 |
Evaluation of high-level carbapenem resistance in atypical Serratia marcescens by a comparison with its revertants.
Topics: Carbapenems; Cell Membrane Permeability; Drug Resistance, Microbial; Evaluation Studies as Topic; Imipenem; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Penicillins; Piperacillin; Serratia marcescens; Thienamycins | 1996 |
In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Drug Interactions; Drug Resistance, Multiple; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 1996 |
Sensitivities to four carbapenems of bacteria isolated from patients with refractory complicated urinary tract infections and the detection of carbapenemase-producing Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins; Urinary Tract Infections | 1996 |
Differential release of smooth-type lipopolysaccharide from Pseudomonas aeruginosa treated with carbapenem antibiotics and its relation to production of tumor necrosis factor alpha and nitric oxide.
Topics: Carbapenems; Ceftazidime; Cephalosporins; Endotoxins; Imipenem; Lipopolysaccharides; Lymphotoxin-alpha; Meropenem; Nitric Oxide; Pseudomonas aeruginosa; Thienamycins; Tumor Necrosis Factor-alpha | 1996 |
Antibacterial activity of T-5575, a novel 2-carboxypenam, and its stability to beta-lactamase.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Gram-Negative Bacteria; Hydrolysis; Imipenem; Kinetics; Mutation | 1997 |
Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein.
Topics: Amino Acid Sequence; Bacterial Outer Membrane Proteins; beta-Lactam Resistance; beta-Lactamases; Blotting, Southern; Carbapenems; Disease Outbreaks; DNA, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Infant; Isoelectric Focusing; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids | 1997 |
Increasing incidence of carbapenem-resistant Pseudomonas aeruginosa bacteraemia in a cancer centre over a seven-year period.
Topics: Bacteremia; Carbapenems; Cross Infection; Drug Resistance, Microbial; Humans; Imipenem; Incidence; Pseudomonas Infections; Retrospective Studies; Thienamycins | 1997 |
In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
Topics: Animals; Carbapenems; Ceftazidime; Cephalosporins; Culture Media; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Imipenem; In Vitro Techniques; Male; Meropenem; Mice; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1997 |
Structure-activity relationships of carbapenem compounds to anti-Haemophilus influenzae activity and affinity for penicillin-binding proteins. Effect of 1 beta-methyl group and C-2 side chain.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Carrier Proteins; Haemophilus influenzae; Hexosyltransferases; Imipenem; Meropenem; Methylation; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Penicillins; Peptidyl Transferases; Protein Binding; Structure-Activity Relationship; Thienamycins | 1997 |
Diffusion of carbapenems through the outer membrane of enterobacteriaceae and correlation of their activities with their periplasmic concentrations.
Topics: Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Carbapenems; Cell Membrane Permeability; Diffusion; Enterobacter cloacae; Enterobacteriaceae; Escherichia coli; Genes, Bacterial; Imipenem; Meropenem; Thienamycins | 1996 |
Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.
Topics: Bacteremia; Carbapenems; Drug Administration Schedule; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 1997 |
Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids coding for class B beta-lactamase.
Topics: Anti-Infective Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cephalosporinase; Hydrolysis; Imipenem; Isoelectric Focusing; Microbial Sensitivity Tests; Ofloxacin; Plasmids; Porins; Pseudomonas aeruginosa; Thienamycins | 1996 |
Susceptibility testing of Stenotrophomonas maltophilia to carbapenems.
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Pseudomonadaceae; Thienamycins | 1997 |
In vitro postantibiotic effect of imipenem and enoxacin alone and in combination against Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Carbapenems; Drug Therapy, Combination; Enoxacin; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 1997 |
Comparison of postantibiotic effects of imipenem and netilmicin alone and in combination against Pseudomonas aeruginosa.
Topics: Carbapenems; Drug Therapy, Combination; Gentamicins; Humans; Imipenem; Microbial Sensitivity Tests; Netilmicin; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Tract Infections | 1997 |
Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Carbapenems; Dipeptidases; Imipenem; Kidney; Methicillin Resistance; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Muscle, Skeletal; Sepsis; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1997 |
In vitro evaluation of BO-3482, a novel dithiocarbamate carbapenem with activity against methicillin-resistant staphylococci.
Topics: Anti-Bacterial Agents; Carbapenems; Gram-Positive Bacteria; Imipenem; Kinetics; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus; Vancomycin | 1997 |
Low-level release of Shiga-like toxin (verocytotoxin) and endotoxin from enterohemorrhagic Escherichia coli treated with imipenem.
Topics: Bacterial Toxins; Carbapenems; Endotoxins; Escherichia coli; Imipenem; Kinetics; Shiga Toxin 1 | 1997 |
Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams.
Topics: Amdinocillin; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cefoxitin; Cell Membrane Permeability; Imipenem; Mutation; Proteus mirabilis | 1997 |
[Survey of sensitivities of clinical isolates to antibacterial agents (annual report)].
Topics: 4-Quinolones; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Carbapenems; Cephalosporins; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Positive Cocci; Haemophilus influenzae; Humans; Imipenem; Meropenem; Monobactams; Penicillins; Pseudomonas aeruginosa; Serratia marcescens; Thienamycins | 1997 |
[In vitro combination effect of vancomycin and carbapenems against carbapenem-resistant MRSA].
Topics: Anti-Bacterial Agents; Carbapenems; Imipenem; Meropenem; Methicillin Resistance; Staphylococcus aureus; Thienamycins; Vancomycin | 1997 |
[A novel carbapenem active against imipenem resistant strains of Pseudomonas aeruginosa].
Topics: Animals; beta-Lactam Resistance; Carbapenems; Imipenem; Kinetics; Mutation; Pseudomonas aeruginosa; Thienamycins | 1997 |
In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem.
Topics: Administration, Oral; Animals; Bacterial Infections; Bacterial Proteins; beta-Lactamases; Carbapenems; Carrier Proteins; Cefmenoxime; Cefpodoxime; Ceftizoxime; Cephalosporins; Drug Stability; Hexosyltransferases; Imipenem; Mice; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Peptidyl Transferases; Pneumonia, Staphylococcal; Prodrugs; Thienamycins | 1997 |
Soluble penicillin-binding protein 2a: beta-lactam binding and inhibition by non-beta-lactams using a 96-well format.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Binding Sites; Binding, Competitive; Biotechnology; Carbapenems; Carrier Proteins; Chemical Precipitation; Dimethyl Sulfoxide; Enzyme Inhibitors; Hexosyltransferases; Imidazoles; Imipenem; Kinetics; Methods; Micropore Filters; Muramoylpentapeptide Carboxypeptidase; Penicillin G; Penicillin-Binding Proteins; Peptidyl Transferases; Recombinant Proteins; Sensitivity and Specificity; Solubility; Triazines; Tritium | 1998 |
Gram-negative bacilli isolated from patients in intensive care unit: prevalence and antibiotic susceptibility.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Blood; Carbapenems; Cephalosporins; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Gram-Negative Bacteria; Humans; Imipenem; Intensive Care Units; Microbial Sensitivity Tests; Respiratory Tract Infections; Saudi Arabia; Urinary Tract Infections; Wounds and Injuries | 1997 |
[The antimicrobial susceptibilities and serotypes of Pseudomonas aeruginosa isolated from sputum].
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Monobactams; Penicillins; Piperacillin; Pseudomonas aeruginosa; Serotyping; Sputum; Thienamycins | 1998 |
Antibiotic-induced lipopolysaccharide (LPS) release from Salmonella typhi: delay between killing by ceftazidime and imipenem and release of LPS.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Carrier Proteins; Ceftazidime; Cephalosporins; Galactose; Hexosyltransferases; Imipenem; Lipopolysaccharides; Membranes; Microbial Sensitivity Tests; Models, Biological; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Peptidyl Transferases; Salmonella typhi; Time Factors | 1998 |
Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meni
Topics: Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Cephalosporins; Child; Drug Therapy, Combination; Humans; Imipenem; Meningitis, Pneumococcal; Meropenem; Microbial Sensitivity Tests; Penicillin Resistance; Streptococcus pneumoniae; Thienamycins; Vancomycin | 1998 |
Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
Topics: Carbapenems; Cilastatin; Drug Combinations; Drug Costs; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Protease Inhibitors; Thienamycins | 1998 |
Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Drug Interactions; Drug Resistance, Microbial; Enzyme Induction; Hydrolysis; Imipenem; Klebsiella; Lactams; Microbial Sensitivity Tests | 1998 |
Identification of the catalytic triad of the protein D2 protease in Pseudomonas aeruginosa.
Topics: Alanine; Amino Acid Substitution; Asparagine; Aspartic Acid; Carbapenems; Catalysis; Endopeptidases; Glutamine; Histidine; Imipenem; Ion Channels; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Porins; Pseudomonas aeruginosa; Serine | 1998 |
Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain.
Topics: Acinetobacter; Acinetobacter Infections; Aged; Aged, 80 and over; beta-Lactam Resistance; Carbapenems; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1998 |
Carbapenemase-producing Pseudomonas aeruginosa in UK.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Enzyme Inhibitors; Gentamicins; Humans; Imipenem; Meropenem; Metalloproteins; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United Kingdom | 1998 |
Novel dithiocarbamate carbapenems with anti-MRSA activity.
Topics: Animals; Bacterial Proteins; Blood Proteins; Carbapenems; Carrier Proteins; Colony Count, Microbial; Dipeptidases; Hexosyltransferases; Humans; Imipenem; Kidney; Male; Methicillin Resistance; Mice; Mice, Inbred ICR; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Penicillins; Peptidyl Transferases; Protein Binding; Rats; Seizures; Staphylococcus aureus; Structure-Activity Relationship; Swine; Thienamycins | 1998 |
In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria.
Topics: Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Methicillin Resistance; Microbial Sensitivity Tests | 1998 |
[Antimicrobial activity of carbapenem antibiotics against gram-negative bacilli].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Imipenem; Meropenem; Monobactams; Norfloxacin; Tetracycline; Thienamycins | 1998 |
In vitro activities of aminomethyl-substituted analogs of novel tetrahydrofuranyl carbapenems.
Topics: Bacteria; Carbapenems; Humans; Imipenem; Microbial Sensitivity Tests; Stereoisomerism; Thienamycins; Time Factors | 1999 |
The production of a novel carbapenem-hydrolysing beta-lactamase in Aeromonas veronii biovar sobria, and its association with imipenem resistance.
Topics: Aeromonas; beta-Lactamases; Carbapenems; Drug Resistance, Microbial; Imipenem; Isoelectric Focusing; Thienamycins; Water Microbiology | 1998 |
Relationship between morphological changes and endotoxin release induced by carbapenems in Pseudomonas aeruginosa.
Topics: Carbapenems; Endotoxins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1999 |
Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina.
Topics: Acinetobacter; Argentina; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Humans; Imipenem; Isoelectric Focusing; Meropenem; Microbial Sensitivity Tests; Molecular Weight; Species Specificity; Sputum; Thienamycins; Urine | 1999 |
In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests.
Topics: Bacteria, Aerobic; Bacteria, Anaerobic; Carbapenems; Enterobacteriaceae; Imipenem; Microbial Sensitivity Tests | 1999 |
[Survey of the sensitivities of clinical isolates to antibacterial agents (annual report)].
Topics: Carbapenems; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins; Time Factors | 1999 |
In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Carrier Proteins; Cefdinir; Cephalosporins; Dipeptidases; Drug Stability; Escherichia coli Proteins; Hexosyltransferases; Imipenem; Lactams; Levofloxacin; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Ofloxacin; Penicillin-Binding Proteins; Peptidoglycan Glycosyltransferase; Peptidyl Transferases; Protein Binding; Serine-Type D-Ala-D-Ala Carboxypeptidase; Thienamycins | 1999 |
Role of ser-237 in the substrate specificity of the carbapenem-hydrolyzing class A beta-lactamase Sme-1.
Topics: Alanine; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Enterobacteriaceae; Escherichia coli; Hydrolysis; Imipenem; Mutagenesis, Site-Directed; Mutation; Serine; Substrate Specificity | 1999 |
Carbapenem-hydrolysing beta-lactamase from clinical isolates of Pseudomonas aeruginosa in Portugal.
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Humans; Imipenem; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Thienamycins; Urinary Tract Infections | 1999 |
In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Topics: Acinetobacter; Anti-Bacterial Agents; Austria; beta-Lactam Resistance; Carbapenems; Cephalosporins; Enterobacteriaceae; Humans; Imipenem; In Vitro Techniques; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonadaceae; Tazobactam; Thienamycins | 1999 |
[Study on antibiotics susceptibility and mechanism of carbapenem-resistance in clinical isolates of Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; beta-Lactam Resistance; Carbapenems; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Ofloxacin; Pseudomonas aeruginosa; Thienamycins | 1999 |
Low convulsive activity of a new carbapenem antibiotic, DK-35C, as compared with existing congeners.
Topics: Animals; Carbapenems; Cefazolin; Cephalosporins; GABA Agonists; Imipenem; Injections, Intraventricular; Male; Meropenem; Mice; Mice, Inbred ICR; Muscimol; Pentylenetetrazole; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Seizures; Synaptic Membranes; Thienamycins | 1999 |
In vitro activities of novel trans-3,5-disubstituted pyrrolidinylthio-1beta-methylcarbapenems with potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Carrier Proteins; Coagulase; Colony Count, Microbial; Gram-Negative Bacteria; Gram-Positive Bacteria; Hexosyltransferases; Humans; Imipenem; Methicillin Resistance; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Peptidyl Transferases; Pseudomonas aeruginosa; Staphylococcus aureus; Thienamycins; Vancomycin | 2000 |
[In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996-1998].
Topics: Bacteria; Carbapenems; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Penicillins; Piperacillin; Respiratory Tract Infections; Thienamycins; Time Factors | 1999 |
[Antimicrobial activities of meropenem against clinically isolated strains in 1997].
Topics: Bacteria; Carbapenems; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Thienamycins; Time Factors | 1999 |
In vitro antibacterial activity and mechanism of action of J-111,225, a novel 1beta-methylcarbapenem, against transferable IMP-1 metallo-beta-lactamase producers.
Topics: Anti-Bacterial Agents; Bacteria; Bacteroides fragilis; beta-Lactamase Inhibitors; Carbapenems; Drug Therapy, Combination; Enzyme Inhibitors; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Serratia marcescens; Thienamycins | 2000 |
Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Creatinine; Drug Resistance, Microbial; Enterobacter cloacae; Enterobacteriaceae Infections; Half-Life; Imipenem; Kidney Diseases; Male; Meropenem; Penicillinase; Pneumonia, Bacterial; Protein Binding; Rats; Rats, Wistar; Thienamycins; Uranyl Nitrate | 2000 |
[Changes in the antibacterial activity of chemotherapeutic agents (especially carbapenems) for 10 species of clinical isolates between 1994 and 1996. Surveillance group of the sensitivities of clinical isolates to antibacterial agents].
Topics: Bacteria; Carbapenems; Drug Resistance, Microbial; Humans; Imipenem; Japan; Meropenem; Multicenter Studies as Topic; Thienamycins; Time Factors | 2000 |
In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Cystic Fibrosis; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 2000 |
Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; beta-Lactamases; Carbapenems; Child; Cross Infection; Disease Outbreaks; Drug Resistance, Microbial; Drug Resistance, Multiple; Electrophoresis, Gel, Pulsed-Field; Humans; Hydrolysis; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Thienamycins | 2000 |
Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains.
Topics: Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Leukocytes; Meropenem; Neutrophils; Phagocytosis; Thienamycins | 2000 |
Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.
Topics: Amino Acid Sequence; Bacterial Outer Membrane Proteins; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cloning, Molecular; Escherichia coli; Imipenem; Kinetics; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Sequence Homology, Amino Acid; Substrate Specificity; Thienamycins; Transformation, Bacterial | 2001 |
Multiple mobile promoter regions for the rare carbapenem resistance gene of Bacteroides fragilis.
Topics: Bacterial Proteins; Bacteroides fragilis; Base Sequence; beta-Lactamases; Carbapenems; DNA Transposable Elements; Drug Resistance, Microbial; Imipenem; Microbial Sensitivity Tests; Molecular Sequence Data; Promoter Regions, Genetic | 2001 |
Discordant carbapenem susceptibility in Methylobacterium species and its application as a method for phenotypic identification.
Topics: Carbapenems; Drug Resistance, Microbial; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Methylobacterium; Microbial Sensitivity Tests; Phenotype; Thienamycins | 2001 |
Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria.
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Diffusion; Enterobacteriaceae; Imipenem; Meropenem; Microbial Sensitivity Tests; Pyrrolidines; Thienamycins | 2001 |
[Antimicrobial activities of carbapenems and fourth generation cephems against clinically isolated strains].
Topics: Bacteria; Carbapenems; Cefepime; Cefozopran; Cephalosporins; Imipenem; Meropenem; Thienamycins | 2001 |
In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.
Topics: Bacteria, Anaerobic; Carbapenems; Ceftriaxone; Cephalosporins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2002 |
Stability of new carbapenem DA-1131 to renal dipeptidase (dehydropeptidase I).
Topics: Animals; Carbapenems; Dipeptidases; Enzyme Stability; Imipenem; Meropenem; Substrate Specificity; Thienamycins | 2002 |
[Comparative antibacterial activity of carbapenems against P. aeruginosa (1)].
Topics: beta-Lactamases; Carbapenems; Drug Resistance, Microbial; Imipenem; Meropenem; Pseudomonas aeruginosa; Thienamycins | 2001 |
Influence on Enterobacter cloacae metabolism, cell-surface hydrophobicity and motility of suprainhibitory concentrations of carbapenems.
Topics: Carbapenems; Enterobacter cloacae; Humans; Hydrophobic and Hydrophilic Interactions; Imipenem; Meropenem; Movement; Thienamycins; Time Factors | 2001 |
In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Ceftazidime; Doripenem; Humans; Imipenem; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Thienamycins; Urinary Tract Infections | 2002 |
[Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Drug Synergism; Drug Therapy, Combination; Imipenem; Meropenem; Pseudomonas aeruginosa; Thienamycins | 2002 |
[Rapid bactericidal activities of carbapenems against Pseudomonas aeruginosa in simulating human plasma concentrations].
Topics: Carbapenems; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microscopy, Electron, Scanning; Models, Biological; Pseudomonas aeruginosa; Thienamycins | 2002 |
Carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Humans; Imipenem; Infant; Infant, Newborn; Infant, Premature | 2002 |
Carbapenem-resistant Pseudomonas aeruginosa in malaysia producing IMP-7 beta-lactamase.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Child; Humans; Imipenem; Malaysia; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 2002 |
[Antibacterial activity of biapenem against recent clinical isolates].
Topics: Bacteria; Bacterial Infections; beta-Alanine; Carbapenems; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Thienamycins | 2003 |
Effect of basic amino acids on susceptibility to carbapenems in clinical Pseudomonas aeruginosa isolates.
Topics: Amino Acids, Basic; Anti-Bacterial Agents; Aztreonam; Carbapenems; Ceftazidime; Culture Media; Humans; Hydrogen-Ion Concentration; Imipenem; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Thienamycins | 2003 |
Resistance emergence among P. aenrginosa in a rat thigh-abscess model. Comparison of imipenem and meropenem treatment.
Topics: Abscess; Animals; Carbapenems; Drug Resistance, Bacterial; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar; Selection, Genetic; Thienamycins | 2003 |
[Activity of cephems and carbapenems against clinically isolated Mycobacterium abscessus].
Topics: Carbapenems; Cefoxitin; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Thienamycins; Tuberculosis, Pulmonary | 2003 |
Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2.
Topics: Amino Acid Sequence; Bacterial Outer Membrane Proteins; Blotting, Western; Carbapenems; Cloning, Molecular; Drug Resistance, Bacterial; Escherichia coli; Gene Dosage; Hydrolysis; Imipenem; Isoelectric Focusing; Kinetics; Klebsiella oxytoca; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Phenotype; Plasmids; Porins; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins; Transformation, Bacterial | 2003 |
[Clinical efficacy of carbapenems in the treatment of destructive pneumonia and chronic purulent bronchitis].
Topics: Adult; Aged; Anti-Bacterial Agents; Bronchitis, Chronic; Carbapenems; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Imipenem; Injections, Intramuscular; Injections, Intravenous; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Thienamycins | 2003 |
[Proper use of carbapenem antibiotics based on the feature in the treatment of infectious diseases (discussion)]].
Topics: Bacteria; Bacterial Infections; beta-Alanine; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Administration Schedule; Drug Combinations; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Thienamycins; Treatment Failure | 2004 |
Typing and characterization of carbapenem-resistant Acinetobacter calcoaceticus-baumannii complex in a Chinese hospital.
Topics: Acinetobacter baumannii; Acinetobacter calcoaceticus; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactam Resistance; beta-Lactamases; Carbapenems; China; Clavulanic Acid; Cloxacillin; Cross Infection; DNA Fingerprinting; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Enzyme Inhibitors; Genes, Bacterial; Genotype; Imipenem; Isoelectric Focusing; Isoelectric Point; Microbial Sensitivity Tests; Molecular Epidemiology; Sequence Analysis, DNA | 2004 |
[Carbapenemase detection in Acinetobacter baumannii clones resistant to imipenem].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Genotype; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Multicenter Studies as Topic; Spain; Thienamycins | 2004 |
Morphological changes induced by imipenem and meropenem at sub-inhibitory concentrations in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Carbapenems; Cross Infection; Histocytochemistry; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pneumonia; Thienamycins | 2004 |
Is it safe to use carbapenems in patients with a history of allergy to penicillin?
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Cross Reactions; Drug Combinations; Drug Hypersensitivity; Female; Humans; Imipenem; Incidence; Male; Meropenem; Middle Aged; Penicillins; Retrospective Studies; Thienamycins | 2004 |
A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58.
Topics: Acinetobacter baumannii; Acinetobacter Infections; beta-Lactamases; Burn Units; Carbapenems; Cross Infection; Disease Outbreaks; Drug Resistance, Bacterial; France; Hospitals, University; Humans; Imipenem; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Sequence Analysis, DNA | 2005 |
Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Humans; Imipenem; Latin America; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pseudomonas Infections; Ribotyping; Sentinel Surveillance | 2005 |
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Klebsiella pneumoniae; Lactams; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Ofloxacin; Thienamycins | 2004 |
Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amino Acid Sequence; Anti-Bacterial Agents; Argentina; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Humans; Imipenem; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction | 2005 |
Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Colony Count, Microbial; Guinea Pigs; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lung; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Porins; Thienamycins; Treatment Outcome | 2005 |
IMPs, VIMs and SPMs: the diversity of metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospital.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; beta-Lactamases; Brazil; Carbapenems; Hospitals, Teaching; Humans; Imipenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections | 2005 |
Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
Topics: Amino Acid Sequence; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; Carbapenems; Humans; Imipenem; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutation; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thienamycins; Transcription, Genetic | 2005 |
Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Case-Control Studies; Catheterization, Peripheral; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Female; Humans; Hypotension; Imipenem; Logistic Models; Male; Risk Factors; Shock; Spain | 2005 |
Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human.
Topics: Adult; Animals; Anticonvulsants; Area Under Curve; Carbapenems; Drug Interactions; Erythrocytes; Female; Humans; Imipenem; Male; Metabolic Clearance Rate; Rats; Rats, Wistar; Thienamycins; Time Factors; Valproic Acid | 2005 |
Prevalence of decreased susceptibility to carbapenems among Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii and investigation of carbapenemases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Citrobacter freundii; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Prevalence; Serratia marcescens; Thienamycins | 2005 |
Amino acid residues that contribute to substrate specificity of class A beta-lactamase SME-1.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Binding Sites; Carbapenems; Cefotaxime; Codon; Escherichia coli; Imipenem; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Penicillins; Substrate Specificity | 2005 |
Detection of metallo betalactamase producing Pseudomonas aeruginosa in hospitalized patients.
Topics: Agar; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ceftazidime; Edetic Acid; Hospitals; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2005 |
In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Thienamycins | 2005 |
Evaluation of techniques for detection of carbapenem-resistant Klebsiella pneumoniae in stool surveillance cultures.
Topics: Bacteriological Techniques; Carbapenems; Culture Media; Drug Resistance, Bacterial; Evaluation Studies as Topic; Feces; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2005 |
[Evaluation of disk diffusion test for carbapenem sensitivity in Acinetobacter baumannii and Pseudomonas aeruginosa strains].
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Quality Control; Reproducibility of Results; Thienamycins | 2005 |
First report of the carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter baumannii isolates in Italy.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Blood; Carbapenems; Colony Count, Microbial; Disease Outbreaks; Drug Resistance, Bacterial; Hospitals, University; Hydrolysis; Imipenem; Italy; Microbial Sensitivity Tests; Pharynx; Urine; Wounds and Injuries | 2006 |
Identification of extended-spectrum, AmpC, and carbapenem- hydrolyzing beta-lactamases in Escherichia coli and Klebsiella pneumoniae by disk tests.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cefoxitin; Clavulanic Acid; Edetic Acid; Escherichia coli; Humans; Hydrolysis; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2006 |
Emergence of Proteus mirabilis carrying the bla metallo-beta-lactamase gene.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cross Infection; Humans; Imipenem; Microbial Sensitivity Tests; Proteus Infections; Proteus mirabilis | 2006 |
Clinical experiences of the infections caused by extended-spectrum beta-lactamase-producing Serratia marcescens at a medical center in Taiwan.
Topics: Amikacin; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Polymerase Chain Reaction; Serratia Infections; Serratia marcescens; Taiwan | 2006 |
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
Topics: Amikacin; Anti-Infective Agents; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Meropenem; Oxazines; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Urine | 2006 |
Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Carbapenems; Colony Count, Microbial; Doripenem; Drug Resistance, Bacterial; Electrophoresis, Polyacrylamide Gel; Gene Expression; Imipenem; Meropenem; Molecular Weight; Mutation; Pseudomonas aeruginosa; Thienamycins | 2006 |
Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel.
Topics: beta-Lactam Resistance; beta-Lactamases; Carbapenems; Escherichia coli; Humans; Hydrolysis; Imipenem; Israel; Plasmids | 2006 |
Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing.
Topics: Anti-Bacterial Agents; Automation; Carbapenems; Drug Resistance, Bacterial; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Reference Standards; Thienamycins | 2006 |
Carriage of OXA-58 but not of OXA-51 beta-lactamase gene correlates with carbapenem resistance in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2006 |
SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Humans; Imipenem; Kinetics; Microbial Sensitivity Tests; Middle Aged; Serratia Infections; Serratia marcescens | 2006 |
Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Spain; Thienamycins | 2006 |
In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Enterobacteriaceae; Ertapenem; Gram-Negative Bacterial Infections; Humans; Imipenem; Klebsiella; Meropenem; Microbial Sensitivity Tests; Proteus; Sweden; Thienamycins | 2006 |
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
Topics: Animals; beta-Lactams; Carbapenems; Ceftriaxone; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Enterococcus; Ertapenem; Female; Imipenem; Intestines; Klebsiella pneumoniae; Mice; Piperacillin; Sodium Chloride; Time Factors; Vancomycin Resistance | 2007 |
Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacteroides fragilis; Bacteroides Infections; Base Sequence; beta-Lactamases; Carbapenems; DNA Transposable Elements; Drug Resistance, Bacterial; Europe; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Population Surveillance; Thienamycins | 2006 |
Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Carbapenems; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meningitis, Bacterial; Meropenem; Microbial Sensitivity Tests; Middle Aged; Neurosurgical Procedures; Postoperative Complications; Thienamycins; Turkey | 2007 |
Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems.
Topics: Anti-Bacterial Agents; Carbapenems; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Genetic Heterogeneity; Genotype; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Time Factors | 2007 |
Differences in phenotypic and genotypic traits against antimicrobial agents between Acinetobacter baumannii and Acinetobacter genomic species 13TU.
Topics: Acinetobacter; Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genome, Bacterial; Genotype; Humans; Imipenem; Microbial Sensitivity Tests; Phenotype; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
First detection of a VIM-1 metallo-beta-lactamase in a carbapenem-resistant Citrobacter freundii clinical isolate in an acute hospital in Germany.
Topics: Aged, 80 and over; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cilastatin; Ciprofloxacin; Citrobacter freundii; Enterobacteriaceae Infections; Female; Germany; Humans; Imipenem; Polymerase Chain Reaction | 2007 |
Influence of disk preparation on detection of metallo-beta-lactamase-producing isolates by the combined disk assay.
Topics: Agar; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Culture Media; Gram-Negative Bacteria; Humans; Imipenem; Microbial Sensitivity Tests | 2007 |
Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Carrier State; Critical Illness; Endemic Diseases; Female; Gastrointestinal Tract; Humans; Imipenem; Incidence; Intensive Care Units; Male; Middle Aged; Pharynx; Pseudomonas aeruginosa; Pseudomonas Infections; Rectum; Risk Factors | 2007 |
Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Child; Child, Preschool; Drug Resistance, Bacterial; Drug Utilization; Hospital Bed Capacity; Humans; Imipenem; Incidence; Infant; Infant, Newborn; Japan; Microbial Sensitivity Tests; Middle Aged; Practice Patterns, Physicians'; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
Topics: Anti-Bacterial Agents; Carbapenems; DNA Transposable Elements; DNA, Bacterial; Drug Resistance, Bacterial; Gene Dosage; Humans; Imipenem; Meropenem; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins | 2007 |
Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Carbapenems; Cilastatin; Disease Models, Animal; Doripenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Models, Biological; Thienamycins | 2008 |
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
Topics: Acinetobacter; Acinetobacter Infections; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Blotting, Southern; Carbapenems; China; Chloramphenicol; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Hospitals; Humans; Imipenem; Integrons; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Rifampin; Sequence Analysis, DNA | 2007 |
Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Drug Synergism; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Italy; Microbial Sensitivity Tests; Rifampin; Sulbactam | 2007 |
Carbapenem resistance in clinical isolates of Pseudomonas aeruginosa.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Carbapenems; Codon, Terminator; Drug Resistance, Bacterial; Glutamine; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Porins; Pseudomonas aeruginosa; Repressor Proteins; Sequence Analysis, DNA; Thienamycins | 2007 |
Preferential selection of IMP and VIM metallo-beta-lactamases by imipenem in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Binding, Competitive; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2007 |
CarO, an Acinetobacter baumannii outer membrane protein involved in carbapenem resistance, is essential for L-ornithine uptake.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Biological Transport; Carbapenems; Cells, Cultured; Drug Resistance, Bacterial; Imipenem; Ornithine; Temperature; Time Factors | 2007 |
[Imipenem resistance in Gram-negative rods and its consumption between 1999 and 2005].
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; Carbapenems; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Intensive Care Units; Microbial Sensitivity Tests; Retrospective Studies | 2007 |
Genetic diversity of carbapenem-resistant isolates of Acinetobacter baumannii in Europe.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactam Resistance; Carbapenems; Cross Infection; Electrophoresis, Gel, Pulsed-Field; Europe; Genetic Variation; Geography; Humans; Imipenem; Microbial Sensitivity Tests; Random Amplified Polymorphic DNA Technique | 2008 |
[Seven cases of decreased serum valproic acid concentration during concomitant use of carbapenem antibiotics].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anticonvulsants; Carbapenems; Drug Interactions; Drug Therapy, Combination; Epilepsy; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Thienamycins; Valproic Acid | 2007 |
Characterization of genetic diversity of carbapenem-resistant Acinetobacter baumannii clinical strains collected from 2004 to 2007.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genetic Variation; Genotype; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2008 |
Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Chromosomes, Bacterial; Cross Infection; Disease Outbreaks; DNA, Bacterial; Drug Resistance, Bacterial; Edetic Acid; Greece; Humans; Imipenem; Integrons; Isoelectric Focusing; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA | 2008 |
High-level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and decreased porin expression.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Citrobacter freundii; Conjugation, Genetic; Drug Resistance, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Polymerase Chain Reaction; Porins; Sequence Analysis, DNA | 2008 |
Simple and rapid determination of serum carbapenem concentrations by high-performance liquid chromatography.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Chromatography, High Pressure Liquid; Imipenem; Male; Meropenem; Mice; Thienamycins | 2008 |
Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144. II. Biological activities.
Topics: Acetylcysteine; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Diterpenes; Drug Synergism; Humans; Imipenem; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Structure; Staphylococcus aureus; Streptomyces | 2008 |
[Antibiotic susceptibility and molecular mechanisms of cephalosporins resistance in Klebsiella isolates from patients with hospital-acquired infections].
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporin Resistance; Cross Infection; Humans; Imipenem; Klebsiella; Klebsiella Infections; Meropenem; Thienamycins | 2006 |
Contribution of extended-spectrum AmpC (ESAC) beta-lactamases to carbapenem resistance in Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Imipenem; Porins | 2008 |
Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Sequence Analysis, DNA | 2008 |
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Carbapenems; Imipenem; Meropenem; Methicillin Resistance; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Thienamycins | 2008 |
Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefepime; Cefuroxime; Cell Line; Cells, Cultured; Cephalosporins; Cloxacillin; Humans; Hydrogen-Ion Concentration; Imipenem; Meropenem; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Oxacillin; Phagocytosis; Staphylococcus aureus; Thienamycins | 2008 |
In vivo development of carbapenem resistance in clinical isolates of Enterobacter aerogenes producing multiple beta-lactamases.
Topics: Adult; Amino Acid Sequence; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacter aerogenes; Enterobacteriaceae Infections; Fatal Outcome; Humans; Imipenem; Liver Transplantation; Male; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA; Thienamycins | 2008 |
Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
Topics: Adult; Anti-Bacterial Agents; Belgium; beta-Lactamases; beta-Lactams; Carbapenems; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Plasmids | 2008 |
Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Humans; Imipenem; Immunosuppression Therapy; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Pneumonia, Bacterial; Rifampin; Treatment Outcome | 2009 |
Simultaneous determination of three carbapenem antibiotics in plasma by HPLC with ultraviolet detection.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ceftazidime; Chromatography, High Pressure Liquid; Drug Stability; Ertapenem; Humans; Imipenem; Meropenem; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Thienamycins | 2008 |
Carbapenems and SHV-1 beta-lactamase form different acyl-enzyme populations in crystals and solution.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Crystallography, X-Ray; Ertapenem; Imipenem; Meropenem; Molecular Structure; Solutions; Spectrum Analysis, Raman; Thienamycins | 2008 |
In vitro activity of doripenem against Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2009 |
Lucasti et al in the May 2008 issue of Clinical Therapeutics.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Thienamycins | 2008 |
Comparison of in vivo nephrotoxicity in the rabbit by a pyrrolidinyl-thio Carbapenem CW-270031.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Cilastatin; Imipenem; Kidney; Kidney Diseases; Male; Meropenem; Pyrrolidines; Rabbits; Thienamycins | 2008 |
Characterisation of the first VIM metallo-beta-lactamase-producing Pseudomonas aeruginosa clinical isolate in Serbia.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Hospitals, Military; Humans; Imipenem; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Serbia; Serotyping | 2008 |
Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Encephalitis; Humans; Imipenem; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2009 |
Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in-vitro biological activity - part II.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Evaluation, Preclinical; Imipenem; Meropenem; Microbial Viability; Molecular Structure; Structure-Activity Relationship; Sulfonamides; Thienamycins | 2009 |
Efficacy of intravenous infusion of doripenem.
Topics: Carbapenems; Cross Infection; Doripenem; Humans; Imipenem; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated | 2009 |
Clinical and economic consequences of ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Health Care Costs; Hospital Mortality; Humans; Imipenem; Intensive Care Units; Length of Stay; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Severity of Illness Index | 2009 |
OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Escherichia coli; Imipenem; Meropenem; Molecular Sequence Data; Oxacillin; Penicillins; Polymerase Chain Reaction; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Thienamycins | 2009 |
Distribution of different carbapenem resistant clones of Acinetobacter baumannii in Tehran hospitals.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefotaxime; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Hospitals; Humans; Imipenem; Iran; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2009 |
[Convulsive liability of an oral carbapenem antibiotic, tebipenem pivoxil].
Topics: Administration, Oral; Animals; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Imipenem; Infusions, Intravenous; Injections, Intraventricular; Male; Mice; Pentylenetetrazole; Rats; Seizures | 2009 |
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; Carbapenems; Doripenem; Enzyme Inhibitors; Hydrolysis; Imipenem; Kinetics; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2010 |
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
Topics: Algeria; Anti-Bacterial Agents; Base Sequence; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Genome, Bacterial; Hospitals, Military; Imipenem; Isoelectric Focusing; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Phenotype | 2010 |
Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem.
Topics: Animals; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Bridged Bicyclo Compounds, Heterocyclic; Carbapenems; Drug Combinations; Drug Discovery; Imipenem; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship | 2010 |
Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Cost-Benefit Analysis; Decision Support Techniques; Doripenem; Hospitalization; Humans; Imipenem; Intensive Care Units; Length of Stay; Middle Aged; Models, Economic; Monte Carlo Method; Pneumonia, Ventilator-Associated; Probability; Respiration, Artificial; Time Factors; United States | 2010 |
Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Analysis of Variance; Anti-Bacterial Agents; Area Under Curve; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Imipenem; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Sulbactam; Thienamycins | 2010 |
Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Mutation; Porins; Proportional Hazards Models; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2010 |
Mutant prevention concentrations of four carbapenems against gram-negative rods.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Mutation; Phenotype; Pseudomonas aeruginosa; Thienamycins | 2010 |
Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.
Topics: Acinetobacter baumannii; beta-Lactamases; Carbapenems; Doripenem; Genotype; Hospitals; Humans; Imipenem; Meropenem; Oxytocin; Polymerase Chain Reaction; Thienamycins | 2010 |
Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Case-Control Studies; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Treatment Outcome | 2010 |
Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Clinical Trials, Phase III as Topic; Doripenem; Female; Health Resources; Humans; Imipenem; Length of Stay; Male; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Prospective Studies; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2010 |
[Activity of doripenem against anaerobic bacteria].
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Bacteroides fragilis; Carbapenems; Doripenem; Drug Resistance, Microbial; Drug Resistance, Multiple, Bacterial; Gram-Positive Bacteria; Humans; Imipenem; Microbial Sensitivity Tests | 2011 |
Antimicrobial stewardship lessons: do Pseudomonas-sparing agents, such as ertapenem, effectively improve bacterial resistance?
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ertapenem; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam | 2010 |
Detection of outer membrane porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates.
Topics: Antibodies, Bacterial; Carbapenems; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Thienamycins | 2010 |
Variability of the bla(IMP-15)-containing integrons, highly related to In95, on an endemic clone of Pseudomonas aeruginosa in Mexico.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Electrophoresis, Gel, Pulsed-Field; Endemic Diseases; Genetic Variation; Humans; Imipenem; Integrons; Mexico; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2010 |
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
Topics: Bacterial Proteins; beta-Lactamases; Blotting, Western; Carbapenems; Imipenem; Klebsiella pneumoniae; Meropenem; Phylogeny; Porins; Thienamycins | 2010 |
Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Cost-Benefit Analysis; Doripenem; Drug Combinations; Humans; Imipenem; Length of Stay; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Quality-Adjusted Life Years; Young Adult | 2010 |
Stability of doripenem, imipenem and meropenem at elevated room temperatures.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Stability; Drug Storage; Imipenem; Meropenem; Temperature; Thienamycins; Time Factors | 2011 |
Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefotaxime; Ceftazidime; Cephalosporinase; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Imipenem; Kinetics; Microbial Sensitivity Tests; Plasmids | 2010 |
[Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
Topics: Acinetobacter Infections; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Doripenem; Enterobacteriaceae Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas Infections; Spain; Thienamycins | 2010 |
Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Blood; Carbapenems; Disease Models, Animal; Doripenem; Female; Imipenem; Infusions, Intravenous; Lung; Meropenem; Plasma; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Spleen; Thienamycins; Treatment Outcome | 2010 |
In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study.
Topics: Anti-Bacterial Agents; Asia; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pacific Islands; Thienamycins | 2010 |
Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Korea; Meropenem; Microbial Sensitivity Tests; Republic of Korea; Thienamycins; Urinary Tract Infections | 2011 |
Identification of diverse OXA-40 group carbapenemases, including a novel variant, OXA-160, from Acinetobacter baumannii in Pennsylvania.
Topics: Acinetobacter baumannii; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Electrophoresis, Gel, Pulsed-Field; Female; Fluoroquinolones; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Sequence Data; Pennsylvania | 2011 |
Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; Carbapenems; Cytokines; Disease Models, Animal; Doripenem; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lung; Meropenem; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Pneumonia, Bacterial; Thienamycins; Treatment Outcome | 2011 |
Novel genetic environment of the plasmid-mediated KPC-3 gene detected in Escherichia coli and Citrobacter freundii isolates from China.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; China; Citrobacter freundii; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Isoelectric Focusing; Meropenem; Microbial Sensitivity Tests; Middle Aged; Plasmids; Polymerase Chain Reaction; Sequence Analysis, DNA; Thienamycins | 2011 |
Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Topics: Anti-Bacterial Agents; Asia; Australia; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Injections, Intravenous; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Thienamycins | 2011 |
Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae.
Topics: Age Factors; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Case-Control Studies; Chi-Square Distribution; Confidence Intervals; Cross Infection; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Logistic Models; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Odds Ratio; Risk Factors; Thienamycins | 2011 |
High prevalence of metallo-beta-lactamase-producing acinetobacter baumannii in a teaching hospital in Tabriz, Iran.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Female; Hospitals, Teaching; Humans; Imipenem; Iran; Male; Meropenem; Middle Aged; Polymerase Chain Reaction; Prevalence; Thienamycins; Young Adult | 2011 |
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Doripenem; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2011 |
Phenotypic and genotypic screening and clonal analysis of carbapenem-resistant Klebsiella pneumoniae at a single hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Doripenem; Electrophoresis, Gel, Pulsed-Field; Ertapenem; Genotype; Hospitals, Urban; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phylogeny; Polymerase Chain Reaction; Sensitivity and Specificity; Thienamycins; United States | 2011 |
[Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Klebsiella Infections; Klebsiella oxytoca; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2011 |
Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Imipenem; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins | 2011 |
Comparative activity of carbapenem testing: the COMPACT study.
Topics: Africa; Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle East; Thienamycins | 2011 |
Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Thienamycins; Treatment Outcome | 2011 |
Gastrointestinal selective capacity of doripenem, meropenem, and imipenem for carbapenem-resistant gram-negative bacilli in treated patients with pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Rectum; Stenotrophomonas maltophilia; Thienamycins | 2011 |
The laboratory diagnosis of Pseudomonas aeruginosa that produce metallo-β-lactamases in a Dutch tertiary care centre.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Edetic Acid; Humans; Imipenem; Laboratories; Meropenem; Microbial Sensitivity Tests; Netherlands; Pseudomonas aeruginosa; Pseudomonas Infections; Reproducibility of Results; Thienamycins | 2011 |
Carbapenem-resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Chi-Square Distribution; Cluster Analysis; Cross Infection; Electrophoresis, Gel, Pulsed-Field; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Molecular Epidemiology; Republic of Korea; Risk Factors; Statistics, Nonparametric; Thienamycins | 2012 |
[Validity of using imipenem as a representative carbapenems and levofloxacin as a representative fluoroquinolones in antibiotics susceptibility test for enterobacteriaceae].
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Fluoroquinolones; Imipenem; Levofloxacin; Ofloxacin | 2011 |
[Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Thienamycins; Turkey | 2011 |
Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Plasmids; Population Surveillance; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Spain; Thienamycins | 2011 |
The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Drug Utilization; Humans; Imipenem; Longitudinal Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2011 |
Silent spread of IMP-13-producing Pseudomonas aeruginosa belonging to sequence type 621 in Belgium.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; Belgium; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins | 2011 |
Structure-function relationships of CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Algorithms; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Binding Sites; Carbapenems; Cloning, Molecular; Databases, Genetic; Drug Resistance, Bacterial; Escherichia coli; Imipenem; Ionophores; Lipid Bilayers; Porins; Protein Folding; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity | 2011 |
Providencia isolates carrying bla (PER-1) and bla (VIM-2) genes: biofilm-forming capacity and biofilm inhibitory concentrations for carbapenem antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactamases; Biofilms; Carbapenems; Enterobacteriaceae Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Providencia; Thienamycins | 2011 |
Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Genotype; Imipenem; Klebsiella pneumoniae; Longitudinal Studies; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Thienamycins; United States | 2011 |
Carbapenem susceptibility testing errors using three automated systems, disk diffusion, Etest, and broth microdilution and carbapenem resistance genes in isolates of Acinetobacter baumannii-calcoaceticus complex.
Topics: Acinetobacter baumannii; Acinetobacter calcoaceticus; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2011 |
Changes in antimicrobial susceptibility and major clones of Acinetobacter calcoaceticus-baumannii complex isolates from a single hospital in Korea over 7 years.
Topics: Acinetobacter; Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Genotype; Hospitals; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Republic of Korea; Species Specificity; Thienamycins | 2012 |
In vitro antibacterial activities of doripenem, imipenem, and meropenem against recent Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Streptococcus pneumoniae; Thienamycins | 2011 |
Molecular characterisation of multiple drug-resistant Acinetobacter baumannii isolates in southern Taiwan.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Multiplex Polymerase Chain Reaction; Taiwan | 2011 |
Emergence and clonal dissemination of carbapenem-hydrolysing OXA-58-producing Acinetobacter baumannii isolates in Bolivia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Bolivia; Carbapenems; Child; Child, Preschool; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Hospitals; Humans; Imipenem; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Middle Aged; Plasmids; Young Adult | 2012 |
[Can meropenem E-test be used to estimate the presence of carbapenem resistance gene cfiA among Bacteroides fragilis strains?].
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacteroides fragilis; Bacteroides Infections; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Feces; Humans; Imipenem; Meropenem; Metalloproteins; Microbial Sensitivity Tests; Thienamycins; Turkey | 2011 |
Characteristics of carbapenem-resistant Acinetobacter spp. other than Acinetobacter baumannii in South Korea.
Topics: Acinetobacter; Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacteremia; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; Carbapenems; Cross Infection; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Real-Time Polymerase Chain Reaction; Republic of Korea | 2012 |
Imipenem: a potent inducer of multidrug resistance in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Gene Expression Regulation, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Mutation; Nuclear Proteins; Reverse Transcriptase Polymerase Chain Reaction; Selection, Genetic | 2012 |
Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Escherichia coli; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Propensity Score; Thienamycins | 2012 |
Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Acute Disease; Animals; Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Colistin; Cytokines; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Female; Imipenem; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pneumonia, Bacterial; Stem Cells; Thienamycins | 2012 |
Evaluation of doripenem in an experimental model of resistant Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactam Resistance; Carbapenems; Colony Count, Microbial; Disease Models, Animal; Doripenem; Humans; Imipenem; Lung; Meropenem; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Thienamycins; Treatment Outcome | 2012 |
Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model.
Topics: Anti-Bacterial Agents; Area Under Curve; Carbapenems; Ciprofloxacin; Doripenem; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Models, Biological; Mutation; Predictive Value of Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Prognosis; Pseudomonas aeruginosa; Pseudomonas Infections; Reference Standards; Thienamycins | 2012 |
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; beta-Lactams; Carbapenems; Cefoxitin; Ceftriaxone; Conjugation, Genetic; Disease Models, Animal; Drug Administration Schedule; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Kidney; Mice; Microbial Sensitivity Tests; Mutation Rate; Plasmids; Urinary Bladder; Urinary Tract Infections | 2012 |
Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Intraabdominal Infections; Microbial Sensitivity Tests; Prevalence; South Africa | 2012 |
Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Topics: Bacteremia; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Germany; Humans; Imipenem; Intensive Care Units; Intraabdominal Infections; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quality Control; Thienamycins | 2012 |
In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Colistin; Drug Therapy, Combination; Fosfomycin; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymerase Chain Reaction; Thailand; Time Factors | 2011 |
[Carbapenem resistance in Pseudomonas aeruginosa isolates: an example of interaction between different mechanisms].
Topics: Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; DNA Mutational Analysis; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Humans; Imipenem; Membrane Transport Proteins; Meropenem; Mutation; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thienamycins | 2011 |
Class A carbapenemase FPH-1 from Francisella philomiragia.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins | 2012 |
Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.
Topics: Animals; beta-Lactams; Carbapenems; Cell Line; Doripenem; Ertapenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Peritonitis; Salmonella; Thienamycins | 2012 |
Characterisation and clonal dissemination of OXA-23-producing Acinetobacter baumannii in Tabriz, northwest Iran.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cross Infection; DNA Transposable Elements; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Imipenem; Integrons; Iran; Microbial Sensitivity Tests; Molecular Epidemiology; Multiplex Polymerase Chain Reaction; Polymerase Chain Reaction; Sequence Analysis, DNA | 2012 |
In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Gram-Negative Bacteria; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Theoretical | 2012 |
Sequence type 101 (ST101) as the predominant carbapenem-non-susceptible Klebsiella pneumoniae clone in an acute general hospital in Italy.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Hospitals, General; Humans; Imipenem; Italy; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2012 |
Proteomic analysis of clinical isolate of Stenotrophomonas maltophilia with blaNDM-1, blaL1 and blaL2 β-lactamase genes under imipenem treatment.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Gene Expression; Gene Expression Regulation, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Phenotype; Proteome; Proteomics; Stenotrophomonas maltophilia | 2012 |
Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Binding Sites; Carbapenems; Ceftazidime; Cephalosporins; Cross Infection; Gene Expression; Humans; Imipenem; Kinetics; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Protein Binding; Protein Isoforms; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Epidemiological and clinical features associated with colonisation/infection by Acinetobacter baumannii with phenotypic heterogeneous resistance to carbapenems.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cohort Studies; Female; Humans; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Risk Factors | 2012 |
OXA-162, a novel variant of OXA-48 displays extended hydrolytic activity towards imipenem, meropenem and doripenem.
Topics: beta-Lactamases; Biocatalysis; Carbapenems; Cloning, Molecular; DNA Transposable Elements; Doripenem; Drug Resistance, Bacterial; Humans; Hydrolysis; Imipenem; Klebsiella pneumoniae; Meropenem; Models, Molecular; Plasmids; Thienamycins | 2013 |
Carbapenem non-susceptible Klebsiella pneumoniae from Micronet network hospitals, Italy, 2009 to 2012.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Hospitals; Humans; Imipenem; Italy; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Sentinel Surveillance; Thienamycins | 2012 |
Doripenem: excess mortality.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Early Termination of Clinical Trials; Evidence-Based Medicine; Humans; Imipenem; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacter; Escherichia coli; Imipenem; Klebsiella oxytoca; Klebsiella pneumoniae; Latin America; Meropenem; Microbial Sensitivity Tests; Minocycline; Serratia marcescens; Thienamycins; Tigecycline; United States; United States Food and Drug Administration | 2012 |
Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Hospitals, University; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Taiwan; Thienamycins | 2012 |
Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pacific Islands; Thienamycins; Time Factors | 2013 |
[Comparison of ertapenem-EMB Agar with traditional methods for screening carbapenem-resistant Klebsiella pneumoniae from rectal swabs].
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Culture Media; Doripenem; Drug Resistance, Bacterial; Ertapenem; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Multiplex Polymerase Chain Reaction; Rectum; Sensitivity and Specificity; Thienamycins; Time Factors | 2012 |
Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland.
Topics: Acinetobacter; Acinetobacter baumannii; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Carbapenems; Doripenem; Enterobacteriaceae; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Poland; Pseudomonas; Species Specificity; Sputum; Thienamycins | 2012 |
A week seems to be weak: tailoring duration of antibiotic treatment in Gram-negative ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Female; Humans; Imipenem; Male; Pneumonia, Ventilator-Associated | 2013 |
Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli.
Topics: Acinetobacter; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Enterobacteriaceae; Imipenem; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Monobactams; Pseudomonas aeruginosa; Thiazoles; Thienamycins | 2013 |
Optimized method for Acinetobacter species carbapenemase detection and identification by matrix-assisted laser desorption ionization-time of flight mass spectrometry.
Topics: Acinetobacter; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Imipenem; Microbial Sensitivity Tests; Picolinic Acids; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Zinc | 2013 |
In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; beta-Lactamase Inhibitors; Carbapenems; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Gram-Positive Bacteria; Humans; Imipenem; Microbial Sensitivity Tests; Prevotella; Serine; Thienamycins | 2013 |
When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Doripenem; Drug Costs; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2013 |
In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients.
Topics: Acinetobacter baumannii; Bacterial Infections; Carbapenems; Doripenem; Electrophoresis, Gel, Pulsed-Field; Europe; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Sensitivity and Specificity; Species Specificity; Thienamycins; United States; United States Food and Drug Administration | 2013 |
IMP-43 and IMP-44 metallo-β-lactamases with increased carbapenemase activities in multidrug-resistant Pseudomonas aeruginosa.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Catalytic Domain; Doripenem; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Hydrophobic and Hydrophilic Interactions; Imipenem; Japan; Meropenem; Phylogeny; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship; Thienamycins | 2013 |
Antibiotic resistance and OXA-type carbapenemases-encoding genes in airborne Acinetobacter baumannii isolated from burn wards.
Topics: Acinetobacter baumannii; Air Microbiology; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Burn Units; Carbapenems; Cefoperazone; Ceftriaxone; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Repetitive Sequences, Nucleic Acid; Sulbactam | 2014 |
[Clonal relatedness of bla(OXA-58)--carrying Acinetobacter baumannii clinical isolates].
Topics: Acinetobacter baumannii; Acinetobacter Infections; beta-Lactamases; Carbapenems; Cloning, Molecular; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests | 2013 |
Carbapenem resistance in Acinetobacter baumannii: where is it heading?
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cross Infection; Hospitals, University; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Prognosis; Risk Factors; Thienamycins; Turkey | 2013 |
In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems.
Topics: Antitubercular Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cell Wall; Clavulanic Acid; Doripenem; Enzyme Assays; Ertapenem; Escherichia coli; Gene Expression; Imipenem; Kinetics; Meropenem; Mycobacterium tuberculosis; Peptidoglycan; Peptidyl Transferases; Recombinant Proteins; Thienamycins | 2013 |
Accumulation of carbapenem resistance mechanisms in VIM-2-producing Pseudomonas aeruginosa under selective pressure.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Humans; Imipenem; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Selection, Genetic; Thienamycins | 2014 |
Types and prevalence of carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex in Northern Taiwan.
Topics: Acinetobacter; Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Electrophoresis, Gel, Pulsed-Field; Genotype; Humans; Imipenem; Microbial Sensitivity Tests; Prevalence; Taiwan | 2014 |
Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Ertapenem; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, General; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Singapore; Thienamycins; Young Adult | 2013 |
[Analysis of the carbapenemase-producing mechanism of Enterobacteriaceae with decreased susceptibility to carbapenems].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Enterobacteriaceae; Ertapenem; Gene Amplification; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Thienamycins | 2013 |
Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Bacterial Load; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Imipenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Sepsis; Sulbactam; Tigecycline; Time Factors | 2013 |
High-level and novel mechanisms of carbapenem resistance in Gram-negative bacteria from tertiary hospitals in Nigeria.
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cluster Analysis; Conjugation, Genetic; Genotype; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Hydrolysis; Imipenem; Microbial Sensitivity Tests; Molecular Typing; Nigeria; Plasmids; Random Amplified Polymorphic DNA Technique; Sequence Analysis, DNA; Tertiary Care Centers; Transformation, Bacterial | 2014 |
Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Female; Genome, Bacterial; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Molecular Epidemiology; Polymerase Chain Reaction; Public Health Surveillance; Survival Analysis; Thienamycins; Treatment Outcome | 2014 |
[In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cefoperazone; Cross Infection; Drug Combinations; Drug Synergism; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Sulbactam; Thienamycins | 2014 |
Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Colistin; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Genotype; Hospitals; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Typing; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2014 |
Increasing resistance rate to carbapenem among blood culture isolates of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa in a university-affiliated hospital in China, 2004-2011.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cephalosporins; China; Drug Resistance, Bacterial; Gram-Negative Bacteria; Hospitals, University; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2015 |
Characterization of a novel Zn²⁺-dependent intrinsic imipenemase from Pseudomonas aeruginosa.
Topics: Bacterial Proteins; Carbapenems; Humans; Imipenem; Pseudomonas aeruginosa; Zinc | 2014 |
Synthetic lethality reveals mechanisms of Mycobacterium tuberculosis resistance to β-lactams.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Female; Imipenem; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Real-Time Polymerase Chain Reaction; RNA, Bacterial; Sequence Analysis, RNA | 2014 |
Reduced production of OprM may promote oprD mutations and lead to imipenem resistance in Pseudomonas aeruginosa carrying an oprD-group 1A allele.
Topics: Alleles; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Carbapenems; DNA, Bacterial; Drug Resistance, Bacterial; Imipenem; Membrane Transport Proteins; Mutation; Porins; Pseudomonas aeruginosa | 2015 |
Description of the OXA-23 β-lactamase gene located within Tn2007 in a clinical isolate of Acinetobacter baumannii from Spain.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; DNA Transposable Elements; Drug Resistance, Bacterial; Humans; Imipenem; Male; Microbial Sensitivity Tests; Spain | 2015 |
First report in China of Enterobacteriaceae clinical isolates coharboring blaNDM-1 and blaIMP-4 drug resistance genes.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Plasmids; Quinolones; Thienamycins | 2015 |
[A comparison of susceptibility of Pseudomonas aeruginosa clinical isolates to carbapenem antibiotics in our hospital].
Topics: Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2014 |
Molecular mechanisms associated with nosocomial carbapenem-resistant Acinetobacter baumannii in Mexico.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Biological Transport; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Hospitals; Humans; Hydrazones; Imipenem; Meropenem; Mexico; Microbial Sensitivity Tests; Thienamycins | 2014 |
Successful containment of carbapenem-resistant Enterobacteriaceae by strict contact precautions without active surveillance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Containment of Biohazards; Cross Infection; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals, Teaching; Humans; Imipenem; Incidence; Infection Control; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phenotype; Prevalence; Prospective Studies; Republic of Korea; Retrospective Studies; Thienamycins | 2014 |
Molecular characteristics of carbapenem-resistant gram-negative bacteria in southern China.
Topics: Anti-Bacterial Agents; ATP-Binding Cassette Transporters; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Drug Resistance, Bacterial; Genes, Bacterial; Glutathione Transferase; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Integrons; Meropenem; Mutagenesis, Insertional; Thienamycins | 2015 |
Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Enterobacter cloacae; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Escherichia coli; Hospitals, Teaching; Humans; Imipenem; Intensive Care Units; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Taiwan; Thienamycins | 2015 |
A novel New Delhi metallo-β-lactamase variant, NDM-14, isolated in a Chinese Hospital possesses increased enzymatic activity against carbapenems.
Topics: Acinetobacter; Acinetobacter Infections; Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; China; Cross Infection; Drug Resistance, Bacterial; Humans; Imipenem; Intensive Care Units; Kinetics; Meropenem; Molecular Sequence Data; Plasmids; Thienamycins | 2015 |
Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Body Surface Area; Burn Units; Burns; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Cohort Studies; Computer Systems; Critical Illness; Drug Combinations; Drug Monitoring; Female; Humans; Imipenem; Length of Stay; Male; Meropenem; Middle Aged; Retrospective Studies; Thienamycins; Young Adult | 2015 |
Rapid induction of high-level carbapenem resistance in heteroresistant KPC-producing Klebsiella pneumoniae.
Topics: Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Carbapenems; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Spectrometry, Mass, Electrospray Ionization | 2015 |
Identification of New Natural CphA Metallo-β-Lactamases CphA4 and CphA5 in Aeromonas veronii and Aeromonas hydrophila Isolates from Municipal Sewage in Central Italy.
Topics: Aeromonas hydrophila; Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Imipenem; Italy; Molecular Sequence Data; Point Mutation; Sewage; Thienamycins | 2015 |
In Vitro Activity of Imipenem and Colistin against a Carbapenem-Resistant Klebsiella pneumoniae Isolate Coproducing SHV-31, CMY-2, and DHA-1.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Hip; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Porins | 2015 |
Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Blood Culture; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Case-Control Studies; Cephalosporins; Ciprofloxacin; Cross Infection; Female; Hospitals; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Mortality; Multivariate Analysis; Odds Ratio; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Severity of Illness Index; Taiwan; Thienamycins | 2017 |
The transferability of blaOXA-23 gene in multidrug-resistant Acinetobacter baumannii isolates from Saudi Arabia and Egypt.
Topics: Acinetobacter baumannii; Bacterial Proteins; Carbapenems; Ceftazidime; Drug Resistance, Multiple, Bacterial; Egypt; Electrophoresis, Gel, Pulsed-Field; Gene Expression Regulation, Bacterial; Genes, Bacterial; Imipenem; Microbial Sensitivity Tests; Molecular Sequence Data; Multilocus Sequence Typing; Plasmids; Saudi Arabia | 2015 |
Intrinsic carbapenem-hydrolyzing oxacillinases from members of the genus Pandoraea.
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Escherichia coli; Imipenem; Piperacillin | 2015 |
[Analysis of the mechanism of drug resistance of VIM-2-type metallo-β-lactamase-producing Acineto- bacter baumannii isolated from burn patients and its homology].
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Burns; Carbapenems; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Sulbactam | 2015 |
Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.
Topics: Azabicyclo Compounds; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Gene Deletion; Gene Expression Regulation, Bacterial; Imipenem; Meropenem; Microbial Sensitivity Tests; Operon; Porins; Pseudomonas aeruginosa; Thienamycins | 2016 |
Interspecies scaling of excretory amounts using allometry - retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine,
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Doripenem; Feces; Fluoroquinolones; Heterocyclic Compounds, 3-Ring; Humans; Imipenem; Linezolid; Naphthyridines; Oxazines; Oxolinic Acid; Pefloxacin; Piperazines; Pyridones; Retrospective Studies; Rifampin | 2016 |
Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Multidrug Resistance-Associated Proteins; Mutation; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Republic of Korea; Thienamycins | 2016 |
Prevalence of bla(PenA) and bla(OXA) in Burkholderia pseudomallei Isolated from Patients at Sappasitthiprasong Hospital and Their Susceptibility to Ceftazidime and Carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Burkholderia pseudomallei; Carbapenems; Ceftazidime; Humans; Imipenem; Melioidosis; Microbial Sensitivity Tests; Prevalence; Real-Time Polymerase Chain Reaction; Thailand | 2016 |
MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2016 |
[Comparison of the modified Hodge test and the Carba NP test for detection of carbapenemases in Enterobacteriaceae isolates].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cilastatin; Enterobacteriaceae; Enzyme Assays; Humans; Imipenem; Microbial Sensitivity Tests; Phenotype; Sensitivity and Specificity | 2016 |
[Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Proteins; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Multiplex Polymerase Chain Reaction; Phenotype; Thienamycins; Turkey | 2016 |
Comparative In Vitro Efficacy of Doripenem and Imipenem Against Multi-Drug Resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cross-Sectional Studies; Doripenem; Drug Resistance, Multiple; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2016 |
Emergence of Serratia marcescens isolates possessing carbapenem-hydrolysing β-lactamase KPC-2 from China.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; China; DNA, Bacterial; Ertapenem; Female; Genotype; Hospitals; Humans; Hydrolysis; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Molecular Typing; Polymerase Chain Reaction; Serratia Infections; Serratia marcescens; Thienamycins; Young Adult | 2016 |
Structural Insights into Recognition of Hydrolyzed Carbapenems and Inhibitors by Subclass B3 Metallo-β-Lactamase SMB-1.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; beta-Lactamases; Captopril; Carbapenems; Catalytic Domain; Crystallography, X-Ray; Doripenem; Imipenem; Meropenem; Mesna; Protein Structure, Secondary; Protein Structure, Tertiary; Serratia marcescens; Thienamycins | 2016 |
Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cross Infection; Doripenem; Humans; Imipenem; Iran; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2016 |
Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Biofilms; Carbapenems; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Minocycline; Sulbactam; Thienamycins; Tigecycline | 2016 |
Modification and evaluation of the Carba NP test by use of paper strip for simple and rapid detection of carbapenemase-producing Enterobacteriaceae.
Topics: Bacterial Proteins; Bacteriological Techniques; beta-Lactamases; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Enterobacteriaceae; Enterobacteriaceae Infections; Enzyme Assays; Humans; Imipenem; Phenotype; Polymerase Chain Reaction; Pseudomonas; Reagent Strips | 2016 |
Inhibition of LpxC Increases Antibiotic Susceptibility in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amidohydrolases; Amikacin; Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Carbapenems; Drug Resistance, Multiple, Bacterial; Imipenem; Microbial Sensitivity Tests; Minocycline; Rifampin; Tigecycline; Vancomycin | 2016 |
Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Thienamycins; Treatment Outcome | 2016 |
Evaluation of different pretreatment protocols to detect accurately clinical carbapenemase-producing Enterobacteriaceae by MALDI-TOF.
Topics: Acinetobacter; Anti-Bacterial Agents; Bacteria; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clinical Laboratory Techniques; Enterobacter aerogenes; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Hydrolysis; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2016 |
First Detection of VIM-4-Producing Pseudomonas aeruginosa and OXA-48-Producing Klebsiella pneumoniae in Northeastern (Annaba, Skikda) Algeria.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Algeria; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Multilocus Sequence Typing; Pseudomonas aeruginosa | 2017 |
Comparison of the Modified-Hodge test, Carba NP test, and carbapenem inactivation method as screening methods for carbapenemase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Enterobacteriaceae; Ertapenem; Imipenem; Meropenem; Microbial Sensitivity Tests; Sensitivity and Specificity; Thienamycins | 2016 |
Boronic acid disk diffusion for the phenotypic detection of polymerase chain reaction-confirmed, carbapenem-resistant, gram-negative bacilli isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Boronic Acids; Carbapenems; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meropenem; Phenotype; Polymerase Chain Reaction; Thienamycins | 2016 |
High prevalence of bla
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Brazil; Carbapenems; Gram-Positive Bacteria; Imipenem; Integrons; Microbial Sensitivity Tests; Molecular Typing; Polymerase Chain Reaction; RNA, Ribosomal, 16S; Soil Microbiology | 2016 |
Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10-year study.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Drug Utilization; Gentamicins; Hospitals; Humans; Imipenem; Meropenem; Pseudomonas aeruginosa; Serbia; Thienamycins | 2016 |
Imipenem represses CRISPR-Cas interference of DNA acquisition through H-NS stimulation in Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Clustered Regularly Interspaced Short Palindromic Repeats; CRISPR-Cas Systems; DNA-Binding Proteins; DNA, Bacterial; Drug Resistance, Bacterial; Genome, Bacterial; Humans; Imipenem; Klebsiella pneumoniae; Plasmids | 2016 |
In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Taiwan; Thienamycins | 2016 |
Isolation of Escherichia coli ST131 producing KPC-2 in Bulgaria.
Topics: Bacterial Proteins; Bacterial Typing Techniques; beta-Lactamases; Bulgaria; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cefotaxime; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Microbial Sensitivity Tests; Phylogeny; Plasmids | 2017 |
Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Topics: Acinetobacter baumannii; Amikacin; Anti-Infective Agents; Asia; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacter; Ertapenem; Gram-Negative Bacteria; Hospitalization; Humans; Imipenem; Intraabdominal Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Urinary Tract Infections | 2017 |
Molecular epidemiology of bla
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; Carbapenems; China; Cross Infection; Drug Resistance, Multiple, Bacterial; Follow-Up Studies; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Epidemiology; Multilocus Sequence Typing | 2017 |
Emergence of Imipenem-Resistant Pseudomonas aeruginosa Clinical Isolates from Egypt Coharboring VIM and IMP Carbapenemases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Egypt; Humans; Imipenem; Inosine Monophosphate; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2017 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefoxitin; Community-Acquired Infections; Cross Infection; Enterobacteriaceae; Ertapenem; Escherichia coli; Humans; Imipenem; Intensive Care Units; Intraabdominal Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Turkey; Urinary Tract Infections | 2017 |
Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Critical Care; Doripenem; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Gene Expression; Genotype; Humans; Imipenem; Klebsiella; Klebsiella Infections; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Thienamycins; United States | 2017 |
Molecular epidemiology and antimicrobial resistance phenotypes of Acinetobacter baumannii isolated from patients in three hospitals in southern Vietnam.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cluster Analysis; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Female; Hospitals; Humans; Imipenem; Longitudinal Studies; Male; Middle Aged; Molecular Epidemiology; Multilocus Sequence Typing; Phenotype; Prevalence; Tandem Repeat Sequences; Vietnam; Young Adult | 2017 |
WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cyclooctanes; Drug Discovery; Drug Resistance, Multiple, Bacterial; Drug Synergism; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2017 |
The prevalence and resistance patterns of Pseudomonas aeruginosa in a tertiary care hospital in Kosovo.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Hospitals, University; Humans; Imipenem; Intensive Care Units; Kosovo; Male; Meropenem; Microbial Sensitivity Tests; Prevalence; Pseudomonas Infections; Retrospective Studies; Tertiary Care Centers; Thienamycins | 2017 |
IMI-2 carbapenemase in a clinical Klebsiella variicola isolated in the UK.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Ertapenem; Gene Transfer, Horizontal; Humans; Imipenem; Klebsiella; Meropenem; Plasmids; Thienamycins; United Kingdom | 2017 |
Comparison of imipenem and meropenem antibiotics for the MALDI-TOF MS detection of carbapenemase activity.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacteriological Techniques; beta-Lactamases; Carbapenems; Enterobacteriaceae; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thienamycins | 2017 |
Formulation of carbapenems loaded gold nanoparticles to combat multi-antibiotic bacterial resistance: In vitro antibacterial study.
Topics: Anti-Bacterial Agents; Carbapenems; Gold; Imipenem; Metal Nanoparticles; Microbial Sensitivity Tests; Thienamycins | 2017 |
Understanding Carbapenem Translocation through OccD3 (OpdP) of Pseudomonas aeruginosa.
Topics: Bacterial Proteins; Binding Sites; Carbapenems; Imipenem; Ion Channels; Lipid Bilayers; Membranes, Artificial; Meropenem; Mutagenesis, Site-Directed; Pseudomonas aeruginosa; Substrate Specificity; Thienamycins | 2017 |
Differential flap dynamics in l,d-transpeptidase2 from mycobacterium tuberculosis revealed by molecular dynamics.
Topics: beta-Lactams; Carbapenems; Ertapenem; Imipenem; Meropenem; Molecular Dynamics Simulation; Mycobacterium tuberculosis; Principal Component Analysis; Thienamycins | 2017 |
Isolation and Whole-genome Sequence Analysis of the Imipenem Heteroresistant Acinetobacter baumannii Clinical Isolate HRAB-85.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; DNA, Bacterial; Drug Resistance, Bacterial; Female; Genome, Bacterial; Genomic Islands; Humans; Imipenem; Multilocus Sequence Typing; Whole Genome Sequencing | 2017 |
Trends in Antimicrobial Resistance against Enterobacteriaceae Strains Isolated from Blood: A 10-year Epidemiological Study in Mainland China (2004-2014).
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; China; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli; Humans; Imipenem; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2017 |
A carbapenem antibiotic imipenem/cilastatin induces an oxidative stress-status and gonadotoxic effects in « wistar » rats.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Dose-Response Relationship, Drug; Drug Combinations; Imipenem; Male; Oxidative Stress; Rats; Rats, Wistar; Spermatozoa; Testis | 2017 |
A general reaction mechanism for carbapenem hydrolysis by mononuclear and binuclear metallo-β-lactamases.
Topics: beta-Lactamases; Carbapenems; Hydrolysis; Imipenem; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Dynamics Simulation; X-Ray Absorption Spectroscopy; Zinc | 2017 |
Shifting trends in bacteriology and antimicrobial resistance among gastrointestinal fistula patients in China: an eight-year review in a tertiary-care hospital.
Topics: Adolescent; Adult; Aged; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; China; Digestive System Fistula; Drug Resistance, Bacterial; Escherichia coli; Female; Gram-Negative Bacteria; Humans; Imipenem; Intraabdominal Infections; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Young Adult | 2017 |
Impact of carbapenem restriction on the antimicrobial susceptibility pattern of Pseudomonas aeruginosa isolates in the ICU.
Topics: Adult; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Drug Resistance, Bacterial; Drug Utilization; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2017 |
Is There a Carbapenem MIC Cutoff Value That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem Non-Susceptible Pseudomonas and Acinetobacter Isolates?
Topics: Academic Medical Centers; Acinetobacter; Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Centers for Disease Control and Prevention, U.S.; Drug Resistance, Microbial; Humans; Imipenem; Maryland; Meropenem; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas aeruginosa; Pseudomonas Infections; ROC Curve; Sensitivity and Specificity; Thienamycins; United States | 2017 |
Comparison of MALDI-ToF MS with the Rapidec Carba NP test for the detection of carbapenemase-producing Enterobacteriaceae.
Topics: Acinetobacter baumannii; Bacterial Proteins; Bacteriological Techniques; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Colorimetry; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2018 |
In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Enterobacteriaceae Infections; Humans; Imipenem; Indiana; Klebsiella pneumoniae; Methyltransferases; Microbial Sensitivity Tests; Sisomicin | 2017 |
Photochemical degradation of the carbapenem antibiotics imipenem and meropenem in aqueous solutions under solar radiation.
Topics: Carbapenems; Chromatography, Liquid; Humic Substances; Imipenem; Kinetics; Meropenem; Photolysis; Rivers; Sunlight; Thienamycins; Wastewater; Water; Water Pollutants, Chemical | 2018 |
SPM-1-producing Pseudomonas aeruginosa ST277 clone recovered from microbiota of migratory birds.
Topics: Animal Migration; Animals; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Bird Diseases; Birds; Brazil; Carbapenems; DNA, Bacterial; Drug Resistance, Bacterial; Ducks; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Membrane Transport Proteins; Microbial Sensitivity Tests; Microbiota; Multilocus Sequence Typing; Polymyxin B; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2018 |
Multiple substitutions lead to increased loop flexibility and expanded specificity in
Topics: Acinetobacter baumannii; Amino Acid Sequence; Amino Acid Substitution; Bacterial Proteins; beta-Lactamases; Carbapenems; Catalytic Domain; Cefotaxime; Cloning, Molecular; Crystallography, X-Ray; Doripenem; Escherichia coli; Gene Expression; Genetic Vectors; Imipenem; Kinetics; Models, Molecular; Mutation; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Substrate Specificity | 2018 |
Performance evaluation of BD Phoenix™, an automated microbiology system, for the screening of IMP-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Automation, Laboratory; Bacterial Proteins; Carbapenems; DNA, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Imipenem; Inosine Monophosphate; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2018 |
The mechanism of NDM-1-catalyzed carbapenem hydrolysis is distinct from that of penicillin or cephalosporin hydrolysis.
Topics: beta-Lactamases; Carbapenems; Cephalosporins; Crystallization; Crystallography, X-Ray; Escherichia coli; Hydrolysis; Imipenem; Magnetic Resonance Spectroscopy; Meropenem; Models, Molecular; Penicillins; Thienamycins | 2017 |
Risk Factors Associated With Carbapenem-Resistant
Topics: Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Retrospective Studies; Risk Factors; Thienamycins | 2017 |
An Outbreak of NDM-1-Producing Klebsiella pneumoniae, Associated with OmpK35 and OmpK36 Porin Loss in Tunisia.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Disease Outbreaks; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Plasmids; Porins; Tunisia | 2018 |
The reduction of l-cystine to l-cysteine in the supernatant of A549 cell culture causes imipenem inactivation.
Topics: A549 Cells; Anti-Bacterial Agents; Carbapenems; Culture Media, Serum-Free; Cysteine; Cystine; Dose-Response Relationship, Drug; Humans; Imipenem; Inactivation, Metabolic; Metabolomics; Micrococcus luteus; Oxidation-Reduction | 2018 |
Direct detection of carbapenemase-associated proteins of Acinetobacter baumannii using nanodiamonds coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Biomarkers; Carbapenems; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Humans; Imipenem; Mass Spectrometry; Microbial Sensitivity Tests; Nanodiamonds; Polymerase Chain Reaction; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2018 |
Occurrence and Characterization of Carbapenemase-Producing Enterobacteriaceae in a Tunisian Hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Hospitals; Humans; Imipenem; Microbial Sensitivity Tests; Tunisia | 2018 |
Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
Topics: beta-Lactam Resistance; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Reagent Strips; Sensitivity and Specificity | 2018 |
Molecular and computational approaches to understand resistance of New Delhi metallo β-lactamase variants (NDM-1, NDM-4, NDM-5, NDM-6, NDM-7)-producing strains against carbapenems.
Topics: Amino Acid Sequence; beta-Lactamases; Carbapenems; Hydrogen Bonding; Imipenem; Kinetics; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Structure, Secondary | 2019 |
Outbreak of IMI-1 carbapenemase-producing colistin-resistant Enterobacter cloacae on the French island of Mayotte (Indian Ocean).
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cephalosporins; Colistin; Comoros; Disease Outbreaks; Electrophoresis, Gel, Pulsed-Field; Enterobacter cloacae; Enterobacteriaceae Infections; Ertapenem; Female; Genome, Bacterial; Humans; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Young Adult | 2018 |
In vitro antimicrobial activity of imipenem plus amikacin or polymyxin B against carbapenem-resistant Pseudomonas aeruginosa isolates.
Topics: Amikacin; Anti-Infective Agents; Carbapenems; Drug Resistance, Bacterial; Drug Synergism; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections | 2018 |
Does the intrinsic oxaAb (blaOXA-51-like) gene of Acinetobacter baumannii confer resistance to carbapenems when activated by ISAba1?
Topics: Acinetobacter baumannii; Acinetobacter Infections; Australia; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Disease Outbreaks; DNA Transposable Elements; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Transcriptional Activation | 2018 |
Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Chromosomes, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacter cloacae; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2018 |
Five novel carbapenem-hydrolysing OXA-type β-lactamase groups are intrinsic in Acinetobacter spp.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amoxicillin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Computational Biology; Drug Resistance, Bacterial; Escherichia coli; Gene Knockout Techniques; Hydrolysis; Imipenem; Microbial Sensitivity Tests; Phylogeny | 2018 |
Differential active site requirements for NDM-1 β-lactamase hydrolysis of carbapenem versus penicillin and cephalosporin antibiotics.
Topics: Ampicillin; beta-Lactamases; Carbapenems; Catalytic Domain; Cefotaxime; Cephalosporins; Codon; Drug Resistance, Bacterial; Escherichia coli; High-Throughput Nucleotide Sequencing; Imipenem; Mutation; Penicillins | 2018 |
Characterization of mutations in Escherichia coli PBP2 leading to increased carbapenem MICs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Escherichia coli; Escherichia coli Proteins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillin-Binding Proteins | 2019 |
An improved carbapenem inactivation method, CIMTrisII, for carbapenemase production by Gram-negative pathogens.
Topics: Acinetobacter; Anti-Bacterial Agents; Asia, Southeastern; Bacterial Infections; Bacterial Proteins; beta-Lactamases; Carbapenems; DNA, Bacterial; Enterobacteriaceae; Humans; Imipenem; Japan; Meropenem; Microbial Sensitivity Tests; Nepal; Pseudomonas; Sensitivity and Specificity; Sequence Analysis, DNA; Time Factors | 2019 |
The plasmid-encoded transcription factor ArdK contributes to the repression of the IMP-6 metallo-β-lactamase gene blaIMP-6, leading to a carbapenem-susceptible phenotype in the blaIMP-6-positive Escherichia coli strain A56-1S.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Comparative Genomic Hybridization; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Phenotype; Plasmids; Repressor Proteins; Urine | 2018 |
Inactivation of the oprD porin gene by a novel insertion sequence ISPa195 associated with large deletion in a carbapenem-resistant Pseudomonas aeruginosa clinical isolate.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Gene Components; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Deletion | 2019 |
Transcriptional response of OmpC and OmpF in Escherichia coli against differential gradient of carbapenem stress.
Topics: Anti-Bacterial Agents; Carbapenems; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Escherichia coli; Gene Expression Regulation, Bacterial; Imipenem; Meropenem; Microbial Sensitivity Tests; Porins; RNA, Antisense; RNA, Bacterial; Transcription, Genetic | 2019 |
Impact of specific inhibitors on metallo-β-carbapenemases detected in Escherichia coli and Klebsiella pneumoniae isolates.
Topics: Anti-Bacterial Agents; Ascorbic Acid; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Catalytic Domain; Ciprofloxacin; Citric Acid; Drug Combinations; Drug Synergism; Escherichia coli; Humans; Imipenem; Klebsiella pneumoniae; Malates; Meropenem; Microbial Sensitivity Tests; Zinc | 2019 |
Comparison of adhesin genes expression among Klebsiella oxytoca ESBL-non-producers in planktonic and biofilm mode of growth, and imipenem sublethal exposure.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Biofilms; Carbapenems; Gene Expression Regulation, Bacterial; Genes, Bacterial; Humans; Imipenem; Klebsiella Infections; Klebsiella oxytoca; Microbial Sensitivity Tests; Phenotype | 2019 |
Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Colistin; Cost-Benefit Analysis; Drug Combinations; Europe; Gram-Negative Bacteria; Humans; Imipenem; Length of Stay; National Health Programs; United States; Urinary Tract Infections | 2019 |
Antibiotics with activity against intestinal anaerobes and the hazard of acquired colonization with ceftriaxone-resistant Gram-negative pathogens in ICU patients: a propensity score-based analysis.
Topics: Aged; Anti-Bacterial Agents; Bacteria, Anaerobic; Carbapenems; Ceftriaxone; Cross Infection; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Intensive Care Units; Intestines; Male; Meropenem; Middle Aged; Propensity Score; Retrospective Studies | 2019 |
Structural Insights into the Mechanism of Carbapenemase Activity of the OXA-48 β-Lactamase.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Catalytic Domain; Doripenem; Hydrophobic and Hydrophilic Interactions; Imipenem; Meropenem; Microbial Sensitivity Tests; Protein Structure, Secondary | 2019 |
Carbapenem-resistant
Topics: Carbapenems; Drug Resistance, Bacterial; Geography; Humans; Imipenem; Japan; Meropenem; Pseudomonas aeruginosa; Regression Analysis | 2019 |
Clonal relatedness and resistance characteristics of OXA-24 and -58 producing carbapenem-resistant Acinetobacter baumannii isolates in Tehran, Iran.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Drug Resistance, Bacterial; Humans; Imipenem; Iran; Microbial Sensitivity Tests | 2019 |
Variable performance of different commercial systems for testing carbapenem susceptibility of KPC carbapenemase-producing Escherichia coli.
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Diagnostic Errors; Ertapenem; Escherichia coli; Escherichia coli Infections; Genotype; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Typing; Random Amplified Polymorphic DNA Technique | 2019 |
TiO
Topics: Carbapenems; Catalysis; Imipenem; Meropenem; Photolysis; Sunlight; Titanium; Water Pollutants, Chemical | 2019 |
Insertion sequences and sequence types profile of clinical isolates of carbapenem-resistant A. baumannii collected across India over four year period.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; DNA Transposable Elements; Drug Resistance, Bacterial; Humans; Imipenem; India; Meropenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Polymerase Chain Reaction | 2020 |
Higher rates of carbapenem-related seizures in older hospitalised adults.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ertapenem; Female; Hospitalization; Humans; Imipenem; Logistic Models; Male; Meropenem; Seizures; Singapore | 2020 |
Chemiluminescent Carbapenem-Based Molecular Probe for Detection of Carbapenemase Activity in Live Bacteria.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Proteins; beta-Lactamases; Carbapenems; Humans; Imipenem; Meropenem | 2020 |
Anti‑restriction protein KlcAHS enhances carbapenem resistance.
Topics: Carbapenems; Drug Resistance, Microbial; Gene Expression Regulation, Bacterial; Genes, Bacterial; Imipenem; Kanamycin; Klebsiella; Microbial Sensitivity Tests; Plasmids; RNA, Messenger; Viral Proteins | 2020 |
KPC-producing Enterobacterales with uncommon carbapenem susceptibility profile in Vitek 2 system.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Gammaproteobacteria; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2020 |
Role of Arginine 214 in the Substrate Specificity of OXA-48.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Arginine; Bacterial Proteins; beta-Lactamases; Carbapenems; Crystallography, X-Ray; Drug Resistance, Bacterial; Enterobacteriaceae; Imipenem; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Mutation; Penicillins; Substrate Specificity | 2020 |
Differences between meropenem and imipenem disk to detect carbapenemase in gram-negative bacilli using simplified carbapenem inactivation method.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Sensitivity and Specificity | 2020 |
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Germany; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Interaction of LysM BON family protein domain with carbapenems: A putative mechanism of carbapenem resistance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Protein Domains | 2020 |
Prospective monitoring of carbapenem use and pseudomonal resistance across pediatric institutions.
Topics: Anti-Bacterial Agents; Carbapenems; Child; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2020 |
Mutational Effects on Carbapenem Hydrolysis of YEM-1, a New Subclass B2 Metallo-β-Lactamase from Yersinia mollaretii.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Hydrolysis; Imipenem; Yersinia | 2020 |
Imipenem-relebactam for Treatment of Carbapenem-resistant Gram-negative Bacteria: Where Do We Stand on In Vitro Susceptibility Testing?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Infections; Carbapenems; Colistin; Double-Blind Method; Gram-Negative Bacteria; Humans; Imipenem | 2021 |
First description of antimicrobial resistance in carbapenem-susceptible Klebsiella pneumoniae after imipenem treatment, driven by outer membrane remodeling.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fosfomycin; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Phylogeny; Plasmids; Virulence Factors; Whole Genome Sequencing | 2020 |
Structure-based functional fitness analyses of carbapenemase variants identified among pathogenic carbapenem-resistant Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Docking Simulation | 2020 |
Performance evaluation of automated BD Phoenix NMIC-500 panel for carbapenemase detection in carbapenem-resistant and carbapenem-susceptible Enterobacterales.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacteriological Techniques; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Enterobacteriaceae; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Sensitivity and Specificity | 2020 |
A method to quantify viable carbapenem resistant gram-negative bacteria in treated and untreated wastewater.
Topics: Anti-Bacterial Agents; Bacterial Load; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Ertapenem; Imipenem; Meropenem; Wastewater; Water Purification | 2020 |
Geographical distribution of Enterobacterales with a carbapenemase IMP-6 phenotype and its association with antimicrobial use: An analysis using comprehensive national surveillance data on antimicrobial resistance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Japan; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Phenotype | 2020 |
[Analysis of related factors of carbapenem resistant Klebsiella pneumoniae infection in patients with artificial airway].
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Risk Factors | 2020 |
Development of the computational antibiotic screening platform (CLASP) to aid in the discovery of new antibiotics.
Topics: Anti-Bacterial Agents; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests; Porins | 2021 |
Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Humans; Imipenem; Microbial Sensitivity Tests | 2021 |
Molecular characterization and antibiotic resistance of Acinetobacter baumannii in cerebrospinal fluid and blood.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Blood; Carbapenems; Cerebrospinal Fluid; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests | 2021 |
Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Caenorhabditis elegans; Carbapenems; Drug Combinations; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli; Humans; Imipenem; Microbial Sensitivity Tests; Taiwan | 2022 |
Adaptations of carbapenem resistant
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Physiological; Adult; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Biofilms; Carbapenems; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Environmental Microbiology; Female; Genes, Bacterial; Humans; Imipenem; Integrons; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Risk Factors; Virulence | 2021 |
Antibacterial activity and carbapenem re-sensitizing ability of 1,10-phenanthroline-5,6-dione and its metal complexes against KPC-producing Klebsiella pneumoniae clinical strains.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Coordination Complexes; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phenanthrolines | 2021 |
The prediction values of carbapenemase detection methods and carbapenem susceptibility testing for clinical outcomes of patients with Acinetobacter bacteremia under carbapenem treatment.
Topics: Acinetobacter; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenems; Humans; Imipenem; Microbial Sensitivity Tests; Retrospective Studies | 2022 |
Clinical Characteristics, Risk Factors, and Outcomes of Patients with Polymicrobial
Topics: Adult; Aged; Bacteremia; Carbapenems; Ertapenem; Female; Hospitalization; Humans; Imipenem; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Odds Ratio; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2021 |
Imipenem-Relebactam Susceptibility and Genotypic Characteristics of Carbapenem-Resistant
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Gammaproteobacteria; Imipenem; Microbial Sensitivity Tests | 2021 |
Comparative study of phenotypic-based detection assays for carbapenemase-producing Acinetobacter baumannii with a proposed algorithm in resource-limited settings.
Topics: Acinetobacter baumannii; Algorithms; Bacterial Proteins; beta-Lactamases; Biological Assay; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests | 2021 |
Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2022 |
Towards implementing an antibiotic stewardship programme (ASP) in Ecuador: evaluating antibiotic consumption and the impact of an ASP in a tertiary hospital according to World Health Organization (WHO) recommendations.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Ecuador; Imipenem; Retrospective Studies; Tertiary Care Centers; World Health Organization | 2022 |
Clinical and molecular characteristics and risk factors for patients acquiring carbapenemase-producing and non-carbapenemase-producing carbapenem-nonsusceptible-Enterobacterales bacteremia.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Enterobacteriaceae Infections; Humans; Imipenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Risk Factors | 2022 |
In vitro activity of imipenem/releactam and comparator agents against clinical bacterial isolates from patients with cancer.
Topics: Anti-Bacterial Agents; Carbapenems; Escherichia coli; Gram-Negative Bacteria; Humans; Imipenem; Microbial Sensitivity Tests; Neoplasms; Pseudomonas aeruginosa | 2022 |
Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Escherichia coli; Imipenem; Klebsiella pneumoniae; Lactams; Meropenem; Microbial Sensitivity Tests; Monobactams | 2022 |
A novel Bacteroides metallo-β-lactamase (MBL) and its gene (crxA) in Bacteroides xylanisolvens revealed by genomic sequencing and functional analysis.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacteroides; Bacteroides fragilis; beta-Lactamases; Carbapenems; DNA Transposable Elements; Genomics; Imipenem; Microbial Sensitivity Tests | 2022 |
In vitro activity of nitroxoline against carbapenem-resistant Acinetobacter baumannii isolated from the urinary tract.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Ciprofloxacin; Escherichia coli; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Nitroquinolines; Sulfamethoxazole; Trimethoprim; Urinary Tract; Urinary Tract Infections | 2022 |
The predominance of Klebsiella pneumoniae carbapenemase (KPC-type) gene among high-level carbapenem-resistant Klebsiella pneumoniae isolates in Baghdad, Iraq.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Humans; Imipenem; Iraq; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Humans; Imipenem; Klebsiella pneumoniae; Leg Ulcer; Microbial Sensitivity Tests; Proteus mirabilis | 2022 |
In vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant gram-negative pathogens.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Escherichia coli; Fosfomycin; Humans; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2022 |
Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Infective Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Ceftazidime; Drug Synergism; Escherichia coli; Imipenem; Klebsiella pneumoniae; Polymyxin B; Tetracyclines | 2022 |
Carbapenem antibiotic stress increases bla
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; DNA Copy Number Variations; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2022 |
Carbapenemase-producing Aeromonas species isolated from the urban-impacted Akaki river in Ethiopia.
Topics: Aeromonas; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Ethiopia; Humans; Imipenem; Microbial Sensitivity Tests; Rivers | 2022 |
Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Humans; Imipenem; Meropenem; Tazobactam | 2022 |
Application of 1,1-ADEQUATE and DFT to correct
Topics: Anti-Bacterial Agents; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests | 2022 |
Comparison of carbapenem minimum inhibitory concentrations of Oxacillin-48-like Klebsiella pneumoniae by Sensititre, Vitek 2, MicroScan, and Etest.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Disk Diffusion Antimicrobial Tests; Ertapenem; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Oxacillin | 2022 |
Management of antibacterial therapy of infectious and inflammatory diseases of the urinary tract in children and regional peculiarities during the COVID-19 pandemic.
Topics: Adolescent; Anti-Bacterial Agents; Carbapenems; Child; Child, Preschool; COVID-19 Drug Treatment; Doxycycline; Humans; Imipenem; Infant; Infant, Newborn; Levofloxacin; Microbial Sensitivity Tests; Pandemics; Urinary Tract; Urinary Tract Infections | 2022 |
3-indoleacetonitrile attenuates biofilm formation and enhances sensitivity to imipenem in Acinetobacter baumannii.
Topics: Acetonitriles; Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Biofilms; Carbapenems; Humans; Imipenem; Microbial Sensitivity Tests | 2022 |
Role of Chromosome- and/or Plasmid-Located
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Chromosomes; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Microbial Sensitivity Tests; Plasmids | 2022 |
A Novel Triple Combination To Combat Serious Infections with Carbapenem-Resistant Acinetobacter baumannii in a Mouse Pneumonia Model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Ascorbic Acid; Biological Factors; Carbapenems; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Imipenem; Inflammation; Mice; Microbial Sensitivity Tests; Pneumonia; Transferrins | 2022 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Escherichia coli; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Structural insights into the substrate specificity of IMP-6 and IMP-1 metallo-β-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Imipenem; Meropenem; Microbial Sensitivity Tests; Substrate Specificity | 2022 |
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Lactams; Microbial Sensitivity Tests; Monobactams; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Prevalence of Efflux Pump and Porin-Related Antimicrobial Resistance in Clinical
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefazolin; Cefepime; Cefoxitin; Ceftazidime; Ceftriaxone; Cephalosporins; Drug Resistance, Bacterial; Ertapenem; Humans; Imipenem; Iraq; Klebsiella pneumoniae; Microbial Sensitivity Tests; Porins; Prevalence | 2022 |
Glyphosate and glyphosate-based herbicides (GBHs) induce phenotypic imipenem resistance in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Glycine; Glyphosate; Herbicides; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
Molecular detection of Metallo-Beta-Lactamase and alginate in multidrug resistance
Topics: Alginates; beta-Lactamases; Carbapenems; Cross-Sectional Studies; Drug Resistance, Multiple; Hemolysin Proteins; Humans; Imipenem; Meropenem; Pseudomonas aeruginosa; Virulence Factors | 2022 |
Carbapenem resistance gene crisis in A. baumannii: a computational analysis.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Doripenem; Imipenem; Meropenem; Molecular Docking Simulation | 2022 |
Unveiling the structural features that regulate carbapenem deacylation in KPC-2 through QM/MM and interpretable machine learning.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Humans; Imipenem; Microbial Sensitivity Tests | 2023 |
Phenotypic and genotypic detection of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in Accra, Ghana.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cross-Sectional Studies; Ertapenem; Escherichia coli; Ghana; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Molecular characteristics and genetic analysis of the genes related to carbapenemase, efflux pump, and outer membrane proteins in carbapenem-resistant Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Multilocus Sequence Typing; Porins | 2023 |
Carbapenemase-loaded outer membrane vesicles protect Pseudomonas aeruginosa by degrading imipenem and promoting mutation of antimicrobial resistance gene.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Imipenem; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa | 2023 |
Whole-genome sequence analysis of clinically isolated carbapenem resistant Escherichia coli from Iran.
Topics: Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Colistin; Escherichia coli; Escherichia coli Proteins; Imipenem; Iran; Multilocus Sequence Typing; RNA, Ribosomal, 16S; Tigecycline | 2023 |
Analysis of risk factors associated with healthcare-associated carbapenem-resistant Klebsiella pneumoniae infection in a large general hospital: a case-case-control study.
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Case-Control Studies; Cross Infection; Delivery of Health Care; Drug Resistance, Bacterial; Hospitals, General; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Risk Factors | 2023 |
Molecular docking and dynamic approach to screen the drug candidate against the Imipenem-resistant CarO porin in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Carbapenems; Doripenem; Ertapenem; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation; Porins | 2023 |
Evaluation of combination therapies with colistin in an experimental mouse pneumonia model induced by carbapenem-resistant Acinetobacter baumannii strain.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Imipenem; Mice; Microbial Sensitivity Tests; Sulbactam; Tigecycline | 2023 |
Molecular Dynamic Analysis of Carbapenem-Resistant
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Humans; Imipenem; Klebsiella; Klebsiella pneumoniae; Ligands; Meropenem; Metal Nanoparticles; Microbial Sensitivity Tests; Molecular Dynamics Simulation; Monobactams; Nanoparticles; Pneumonia; Porins; Spectroscopy, Fourier Transform Infrared; Zinc Oxide | 2023 |
Carbapenem Resistance among Klebsiella pneumoniae in a Tertiary Care Hospital in Bangladesh.
Topics: Agar; Anti-Bacterial Agents; Bangladesh; beta-Lactamases; Carbapenems; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Tertiary Care Centers | 2023 |
Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Drug Combinations; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; United States | 2023 |
Epidemiological and Genetic Characteristics of Clinical Carbapenem-Resistant
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ertapenem; Escherichia coli; Hong Kong; Humans; Imipenem; Intensive Care Units; Meropenem; Pseudomonas aeruginosa; Tazobactam | 2023 |
Association of Biofilm Inducer with
Topics: Bacterial Proteins; beta-Lactamases; Biofilms; Carbapenems; Imipenem; Meropenem; Pseudomonas aeruginosa | 2022 |
In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymyxin B | 2023 |
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
[Application of Rapid Detection Method Based on NG-Test® CARBA 5 in Bloodstream Infections Associated With Carbapenem-Resistant Enterobacterales].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Escherichia coli; Humans; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests; Sepsis | 2023 |
Evolution of carbapenem resistance in klebsiella pneumoniae and escherichia coli carrying bla
Topics: Anti-Bacterial Agents; Carbapenems; Escherichia coli; Imipenem; Klebsiella pneumoniae | 2023 |
Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020.
Topics: Anti-Bacterial Agents; Carbapenems; Gammaproteobacteria; Humans; Imipenem; Pseudomonas aeruginosa | 2023 |
Examining the presence of carbapenem resistant Enterobacterales and routes of transmission to bovine carcasses at slaughterhouses.
Topics: Abattoirs; Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cattle; Escherichia coli; Imipenem; Microbial Sensitivity Tests; Multilocus Sequence Typing | 2023 |
In vitro activity of imipenem/relebactam and ceftazidime/avibactam against carbapenem-resistant Klebsiella pneumoniae from blood cultures in a University hospital in Serbia.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Blood Culture; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Ceftazidime; Colistin; Drug Combinations; Hospitals, University; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Serbia | 2023 |
The
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Drug Combinations; Imipenem; Microbial Sensitivity Tests; Mycobacterium abscessus | 2023 |
Characterization of carbapenemase-producing Gram-negative bacilli: first report of blaNDM-1 in Enterobacter cloacae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Enterobacter cloacae; Escherichia coli; Gram-Negative Bacteria; Imipenem; Microbial Sensitivity Tests | 2023 |
Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Drug Combinations; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2023 |
Carbapenem resistance determinants and their transmissibility among clinically isolated Enterobacterales in Lebanon.
Topics: Anti-Infective Agents; Carbapenems; Humans; Imipenem; Lebanon; Meropenem | 2023 |
Occurrence of some common carbapenemase genes in carbapenem-resistant Klebsiella pneumoniae isolates collected from clinical samples in Tabriz, northwestern Iran.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cross-Sectional Studies; Humans; Imipenem; Iran; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2023 |
Colistin-induced structural and biochemical changes in carbapenem-resistant Acinetobacter baumannii isolated from the hospital environment.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Imipenem; Microbial Sensitivity Tests | 2023 |